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Abstract 
 Rabies is a fatal disease that affects the central nervous system of all warm-
blooded mammals. The rabies virus belongs to the order Mononegavirales, family 
Rhabdoviridae, genus Lyssavirus. This virus has a negative single-stranded RNA 
genome and the virions are bullet-shaped. 
Rabies is reported in many countries throughout the world and has been 
registered in all continents except Australia, where only the bat Lyssaviruses have been 
found, and in Antarctica where the main vectors of rabies are absent. Russia and most of 
the bordering countries are affected by rabies. Finland was a rabies-free country from 
1959 to 1988, when a sylvatic rabies epidemic appeared with raccoon dogs as the main 
host and vector of infection. That epidemic was eradicated by the oral vaccination of wild 
carnivores and the parenteral immunization of dogs and cats; and Finland has been 
rabies-free since 1991. However, this status is constantly under threat because rabies is 
endemic in Russia and Estonia. In June 2003, a horse imported to Finland from Estonia 
was clinically and laboratory diagnosed as rabies positive. The close relationship of the 
isolated equine virus strain with the current Estonian strains was verified during 
subsequent molecular epidemiological studies. Because the case was imported, it did not 
affect Finland’s rabies-free status. Also in 2007 another 2 imported cases of rabies were 
recorded: one in a human being from Philippines and the other in a dog from India. 
Five different antigenic variants of the rabies virus were identified among rabies 
positive field samples from Russia, Finland, and Estonia by using antinucleocapsid 
monoclonal antibodies. Two rabies virus field isolates showed a different reaction pattern 
that was similar to that of the vaccine strains of the SAD group, which might suggest a 
new antigen variant or reverted vaccine strain. Nevertheless, the sequence analysis 
showed that the vaccine strains RV-97 and SAD B19 included in the oral anti-rabies 
vaccine “Sinrab” (Russia) and “Fuchsoral” (Germany), respectively, differ considerably 
from all the field strains. 
Field rabies viruses collected in recent years from different regions of the Russian 
Federation were chosen on the basis of mAb studies and geographical origin for 
molecular epidemiological studies to characterize their genetic heterogeneity and to study 
their molecular epidemiology. In addition to the Russian viruses, archival samples from 
Estonia and Finland and Russian vaccine strains were also included in this study. Among 
the field viruses studied, two main phylogenetic groups were found, and designated as 
the Pan-Eurasian and Caucasian based on their geographical origin. The Pan-Eurasian 
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group including some reference viruses from Europe was further divided into four 
subgroups. All the vaccine strains were clearly different from the field strains. No 
recombination between the field and vaccine virus strains was observed. The critical 
roles of geographical isolation, the limitation of the genetic clustering, and the evolution of 
the rabies virus were shown during this study. 
The rabies virus vaccine strain RV-97 is widely used in Russia as a component of 
the oral anti-rabies vaccine “Sinrab”. To characterize the molecular properties of this 
strain, entire genome sequencing was conducted. A simple technique was developed to 
obtain this sequence, including the 3’- and 5’- ends. The entire genome sequence and 
deduced amino-acid sequences of the major viral proteins were compared with the 
sequences of other known fixed rabies viruses. The strain RV-97 formed a separate 
phylogenetic branch and seems to be more related to the group of Japanese strains. The 
field strains from the Caucasian group seem to be phylogenetically the nearest group to 
the RV-97 strain. 
The data shown herein makes it possible to develop molecular methods for 
distinguishing between the field rabies viruses from the vaccine strains for the rapid 
recognition of the vaccine strains that are unstable or have reverted back to their 
pathogenic form. The wide genetic heterogeneity verified in this study indicates that it is 
important to remain on permanent alert for the appearance of rabies. 
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1. Literature review 
 
1.1. Definition and history of rabies 
Rabies is a fatal viral zoonosis which causes encephalitis in many warm-blooded 
animals and humans. There have been indications relative to the occurrence of rabies 
since the time of Homer (eighth century B.C.) onwards. The first archival appearance of 
the disease was in the fourth century B.C., but precise diagnosis was not possible before 
the first century B.C. (Blancou, 1994, 2004; Neville, 2004). The first human rabies 
vaccine was developed in 1885 by Louis Pasteur and since then, significant 
developments have been made in this field including progress in laboratory diagnosis, 
vaccination and rabies control in wild, domestic and farm animals (King et al., 2004). 
 
1.2. Rabies virus characteristics 
1.2.1. Classification 
 The rabies virus belongs to the order Mononegavirales, family Rhabdoviridae, 
which includes at least three genera: Lyssavirus, Ephemerovirus, and Vesiculovirus 
(Virus Taxonomy, 2005). The Lyssavirus genus is further divided into seven genotypes. 
The genotype 1 is known to be the most widespread and comprises the classical field 
rabies viruses, and the laboratory and vaccine strains. The rabies-related viruses isolated 
in the African continent belong to genotypes 2, 3, and 4, with prototypes of the Lagos bat 
virus, Mokola virus, and Duvenhage virus, respectively. The viruses isolated from bats in 
Europe represent genotypes 5 and 6 (EBLV1 and EBLV2). The Australian bat Lyssavirus 
(ABLV) represents the seventh genotype (Gould et al., 1998; Guyatt et al., 2003). 
It has been found that some new rabies virus genotypes exist among viruses 
isolated from the territory of the former Soviet Union. It was proposed that the Aravan 
virus isolated from a bat in Kyrgyzstan should be classified as the eighth genotype (Arai 
et al., 1997). The Khujand virus isolated in Tajikistan can also be classified as a separate 
genotype of Lyssavirus (Kuzmin et al., 2003). The existence of two additional Lyssavirus 
genotypes among strains isolated from bats (Irkut virus and West Caucasian Bat Virus) in 
the Russian Federation was also recently proposed (Botvinkin et al., 2003; Kuzmin et al., 
2005). 
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1.2.2. Structure of virion, genome, and proteins of rabies virus 
The virions of the rabies virus have a bullet-shaped structure (Fig. 1) with a 
diameter of 75 nm and length of 100-300 nm (Matsumoto 1962; Tordo and Poch, 1988). 
The virion contains two major subunits. The first subunit is the ribonucleoprotein (RNP) of 
cylindrical and compact form located in the central part of the virion, the second subunit 
is a thin surrounding envelope covered with spiky projections (Tordo, 1996). 
 
 Figure 1. Rabies virus virions (http://www.wadsworth.org/databank/rabies.html). 
The genome of the rabies virus is a non-segmented negative-sense single-
stranded RNA of approximately 12000 nucleotides (nt) in length (Fig. 2). The virus RNA 
codes 5 major proteins: the nucleoprotein (N protein), phosphoprotein (P protein), matrix 
protein (M protein), glycoprotein (G protein), and the RNA-dependent RNA-polymerase (L 
protein). The RNP complex is formed by the N, P, and L proteins associated with the viral 
RNA. The RNP is surrounded by a lipid bilayer associated with the G and M proteins 
(Goto et al., 2000). The genome also contains several non-coding regions including a G-
L intergenic region called the “pseudogene” or Ψ-region (Fig. 2), which became 
suppressed and degenerated during the evolution of the virus (Tordo et al., 1986). 
 
Figure 2. Schematic structure of the rabies virus genome (adapted from 
http://www.cdc.gov/ncidod/dvrd/rabies/the_virus/virus.htm). 
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The nucleoprotein consists of 450 amino acids and participates in the transition 
from RNA transcription to replication. It encapsidates the positive-strand leader RNA and 
prevents further transcription of the genomic RNA (Wunner, 1991; Yang et al., 1998) and 
contains several antigenic and immunodominant sites. The antigenic sites I and III 
include stretches of amino acids at positions 374-383 and 313-337, respectively (Tordo, 
1996). One of the immunodominant sites is known to be located at position 404-418 
(Dietzschold et al., 1987; Ertl et al., 1989). Recently, the crystal structure of the rabies 
virus nucleoprotein-RNA complex was determined (Albertini et al., 2006). 
The P protein is a phosphorylated protein of 297 amino acids, associated with the 
L protein to function as a noncatalytic cofactor for the RNA polymerization, and with the N 
protein to support adequate RNA encapsidation (Chenik et al., 1994, 1998; Jacob et al., 
2001). Four additional proteins derived from the phosphoprotein gene of the rabies virus 
were also found to be present in infected cells, cells transfected with a plasmid encoding 
the wild-type P protein, and in the purified virus. It was shown that these proteins are 
initiated from secondary downstream in-frame AUG initiation codons. The P-gene is the 
only gene shown to encode more than one protein (Chenic et al., 1995). Two antigenic 
sites were found to be located at positions 75-90 (Tordo, 1996). The domain 83-172 was 
shown to contain the major antigenic determinants (Raux et al., 1997). An 
immunodominant site was also mapped in phosphoprotein at positions 191-206 (Larson 
et al., 1991), and was identified as the responsible alpha/beta interferon antagonist 
(Brozka et al., 2005). 
The matrix protein is a 202 amino acid polypeptide which plays a key role in virus 
assembly and binding. It covers the ribonucleoprotein (RNP) coil to keep it in a 
condensed form and was found to interact specifically with the glycoprotein (Mebatsion et 
al., 1999). The major antigenic site is located between the amino acid residues 1 and 72 
(Hiramatsu et al., 1992). 
The glycoprotein is a 524 amino acid protein and is the most studied protein of the 
rabies virus. It has a trimeric structure (Gaudin et al., 1992), with the first 19 amino acids 
representing the signal domain which is found only in nascent protein. The glycoprotein 
contains several antigenic sites and epitopes. The antigenic epitope I is represented by a 
single amino acid at position 231 of the mature glycoprotein. The site II is known to be 
discontinuous and involves two separate stretches between positions 34-42 and 198-200. 
The antigenic site III is located at position 330-338, epitope VI at position 264, “a” – 342-
343 (Lafon et al., 1983, 1984; Seif et al., 1985; Prehaud et al., 1988; Bunschoten et  
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al., 1989; Benmansour et al., 1991). 
The major immunodominant site of the glycoprotein is located between amino 
acids 222 and 332 (Johnson et al., 2002b). The amino acid at position 333 of the mature 
glycoprotein was found to be associated with viral pathogenicity (Seif et al., 1985; 
Badrane et al., 2001). It was shown that either arginine or lysine at position 333 of the 
ERA and CVS fixed rabies virus strains is necessary for rabies virulence in adult mice 
(Tuffereau et al., 1989). 
The L protein is the largest protein of the rabies virus and L gene occupies more 
than half of the virus genome. It has been the least studied rabies protein at biochemical 
and immunological levels, but the best analyzed theoretically (Tordo, 1996). The L-
protein is associated with the RNP, RNA-dependent RNA polymerase. It participates in 
transcription by making five individual mRNAs, one for each viral protein. 
 
1.3. Virus-host interaction 
1.3.1. Pathogenesis 
 Rabies is a central nervous system (CNS) disease that is almost invariably fatal 
(Dietzschold et al., 2005), except for few rare reported cases (Miah et al., 2005). The site 
of rabies virus entry into the host is usually at the skin or mucosal membrane where the 
virus is introduced into the deeper layers of the skin or into the muscular tissue through 
biting, licking, or scratching by a rabies-infected mammal, usually a carnivore or a bat 
(Charlton, 1994). The transmission of rabies can also occur under unusual 
circumstances: by inhalation of large amounts of aerosolized rabies virus, and through 
organ transplantation from rabies infected patients (Gode and Bhide, 1988; Krebs et al., 
1995; Hellenbrand et al., 2005; Smith et al., 2006). Rabies-infected animals have in their 
salivary glands high titers of the rabies virus, which can be even greater than in the brain 
(Charey and McLean, 1983). There are marked differences between the different strains 
of virus and their ability to infect, spread within the body, and produce disease (Kaplan, 
1996; Dietzschold et al., 2005). It has been suggested that the attenuated rabies viruses 
activate the host’s innate immune and antiviral responses, while these responses are 
evaded by the pathogenic rabies viruses (Wang et al., 2005). The course of the disease 
can be different between animal species: for example, foxes have a comparatively 
shorter morbility period than skunks (Sikes, 1962). 
After the bite (Fig. 3), the virus particles “travel” to the nearby nerves and then 
along the nerve fibers to the brain at a speed of a few millimeters per day (Jackson, 
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1991). It was suggested that the virus is propagated from the entry point to the CNS due 
to the interaction between the P protein of the rabies virus and the dynein light chain LC8 
(Poisson et al., 2001). 
A bite on the head or neck will usually cause symptoms more quickly than a bite 
on the hind leg. However, when the virus has entered the nerve endings, it advances 
relentlessly up the nerve bodies until it reaches the spinal cord and eventually the brain. 
From the brain, the virus can spread to other tissues - the salivary glands, respiratory 
system, and the digestive tract (Krebs et al., 1995). 
 
Figure 3. Spread of the rabies virus from the bite site to the CNS (by Bacon & 
Macdonald, 1980). 
 
1.3.2. Clinical signs 
The clinical signs of rabies are known since the ancient times (Blancou, 1994). 
The duration from bite to the appearance of clinical signs varies significantly, ranging 
from a few days to a several months. The clinical signs may appear only after the 
involvement of numerous neurons, and death may occur as a result from the involvement 
of vital nerve centers (Schneider, 1975). There are three phases described in the clinical 
course of rabies: 
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Prodromal period – the first 1 to 3 days after the rabies virus reaches the brain. 
Vague neurological signs that progress rapidly - some animals may appear tamer, 
some will demonstrate intense drooling. Death usually follows within 10 days, due 
to paralysis. 
 
Excitative stage – the next 2 to 3 days. This is the "furious rabies" stage - tame 
animals suddenly become vicious, attacking humans and other animals as they 
roam and wander. Some animals will chew and eat odd objects (rocks, sticks, 
etc.). Paralysis then begins, and loss of the ability to swallow will cause frothing at 
the mouth of the affected animal. 
 
Paralytic stage - follows the excitative stage, or is the main clinical presentation 
for some animals. The throat and chewing muscles are paralyzed, and the animal 
is unable to swallow, causing excessive drool, the lower jaw is often dropped. This 
is a dangerous period for human contact with domestic animals such as cows and 
horses; "choke" (foreign body within the throat) can be a misdiagnosis of rabies, 
causing humans to be potentially exposed as they investigate the problem. Similar 
situations occur in dogs that appear to be choking (drooling and dropped jaw). 
This is also the period when wild animals may seem tame to humans and 
nocturnal animals are seen in the daylight. The paralysis progresses from the neck 
and jaw to all areas of the body, the animal falls into a coma, and dies within a few 
hours. 
 
In bats, the clinical signs of a Lyssavirus-infection include loss of body mass, lack 
of coordination, muscular spasms, agitation, increased vocalization, and overt aggression 
(Brass, 1994; Whitby et al., 2000; Shankar et al., 2004), but in many cases, rabies in bats 
can be clinically silent and left unnoticed before dead animals are found and laboratory 
tests are performed (Ronsholt et al., 1998). When bats were found alive, the clinical signs 
were generally described as paralysis, unprovoked vocalization, and aggression (biting) 
during handling (Rabies bulletin Europe, 1989). However, almost all bats will bite when 
handled (Vos et al., 2007). 
Because dogs are often responsible for the transmission of rabies to humans, 
clinical signs in this species are more elaborately described, studied, understood, and 
include: drooping jaw, abnormal sounds when barking, dry drooping tongue, licking of it’s  
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own urine, abnormal liking of water, regurgitation, altered behavior, the biting and eating 
of abnormal objects, aggression, biting without provocation, running without no apparent 
reason, stiffness upon running or walking, restlessness, biting during quarantine, sleepy 
appearance, gait imbalance, and frequent demonstration of the “Dog sitting” position 
(Tepsumethanon et al., 2005). 
 
 
 
1.3.3. Pathological changes 
The pathology of rabies infection is typically characterized by encephalitis and 
myelitis. When brain tissue from rabies virus-infected animals is observed with a 
histological stain, such as hematoxylin-and-eosin, evidence of encephalomyelitis may be 
recognized by light microscopy (Fig. 4 A&B). A perivascular non-suppurative infiltration is 
the most frequently noted histological alteration in rabies (Perl, 1975). The cytoplasmic 
eosinophilic inclusion bodies (Negri bodies) can often be found in rabies-infected neurons 
(Fig. 4 C&D), especially in the pyramidal cells of the hippocampus and the Purkinje cells 
of the cerebellum (Negri, 1903). These Negri bodies may vary in size from 0.25 to 27 µm, 
and these inclusions have been defined as areas of active viral replication by the 
identification of rabies viral antigen (Schneider et al., 1975). 
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A. 
 
 
 
B. 
 
C. 
 
 
D. 
Figure 4. A&B. Perivascular cuffing or inflammation around a blood vessel. Perivascular 
inflammatory cell infiltrates in hematoxylin-and-eosin stained brain tissue. C&D. Negri 
bodies stained with hematoxylin and eosin (C) and Sellers stain (D). All pictures were 
taken from http://www.cdc.gov/ncidod/dvrd/rabies/diagnosis/images. 
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1.4. Laboratory diagnosis of rabies 
 The diagnosis of rabies has to be quick and reliable in order to evaluate the risk of 
infection to the exposed individual (Zimmer et al., 1990), and it is also important for health 
authorities responsible for the surveillance and control of the epidemics and epizootics 
(Perrin et al., 1986). The techniques for the diagnosis of rabies are standardized 
internationally, and several tests are available presently. The detection of Negri bodies in 
brain smears and the histological examination were the first methods for diagnosing 
rabies, but these are not currently used widely because of their low sensitivity and due to 
the availability of highly sensitive and specific modern techniques which can be 
subdivided into three main groups: 
 
• Detection of viral antigen – fluorescent antibody test (FAT), enzyme-
linked immunoassay (ELISA), immunohistochemical test (IHCT), and latex 
agglutination test (LAT); 
• Detection and identification of viral genome – reverse transcriptase 
polymerase chain reaction (RT-PCR) with subsequent nucleotide 
sequencing; 
• Virus isolation – mouse inoculation test (MIT) and cell culture inoculation 
test (CCIT). 
The above mentioned methods will be discussed in the specific subchapters 
below. 
 
1.4.1. Detection of viral antigen 
 Fluorescent antibody test. In 1958, Goldwasser and Kissling reported that the 
fluorescent antibody technique could be used to demonstrate rabies virus antigens in 
brain tissues of experimentally infected mice. Further studies have shown this method to 
be an efficient tool for the diagnosis of rabies, and it later became the reference method 
for the diagnosis of this infection (Beauregard et al., 1965). This technique implies the 
preparation of smears, impressions or cryosections from brain tissues (Ammon’s horn, 
cerebellum, cerebral cortex, and the brain stem), tissue fixation, mostly in cold acetone, 
and staining with fluorescein isothiocyanate-labeled polyclonal or monoclonal anti-rabies 
antibodies (Kissling, 1975; Dean et al., 1996; OIE, 2004). The FAT allows specific and 
highly sensitive detection of the rabies virus antigens in brain smears, salivary gland 
sections, and infected cell cultures. It can be used for the intravitam rabies diagnosis in  
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the skin biopsies (Bryceson et al., 1975; Warrell et al., 1988) and to stain rabies virus 
antigens in the salivary glands (Goldwasser et al., 1959). 
It is also possible to perform the FAT with formalin-fixed paraffin-embedded brain 
sections using digestion with proteases, such as pepsin or trypsin (Johnson et al., 1980; 
Umoh and Blenden, 1981; Barnard and Voges, 1982; Reid et al., 1983; Metlin et al., 
2007). 
Enzyme-linked immunoassay test is a rapid technique that facilitates the 
evaluation of a large number of samples simultaneously, which is performed on 
microplates previously sensitized with anti-rabies immunoglobulin. Suspensions of 
homogenized material are placed on the wells of microplate for specific binding which 
can be revealed by the use of a peroxidase conjugate (Perrin et al., 1986). Additionally, a 
quantitative ELISA (N-ELISA) for rabies virus detection based on the quantitation of 
nucleoprotein (N) in rabies virions captured by rabies-virus-specific polyclonal antibodies 
on an ELISA plate can be used for the quantitative detection of both infective and 
defective interfering particles of rabies virus (Katayama et al., 1999). 
Immunohistochemical testing is predominantly used for research purposes and 
allows the perfect identification and localization of rabies virus antigens, and is ideal for 
retrospective diagnosis (Johnson et al., 1980; Fekadu et al., 1982; Torres-Anjel et al., 
1984; Palmer et al., 1985; Shin et al., 2004). This method is usually used to stain 
histological paraffin sections after deparaffinization, rehydration, and digestion with a 
proteolytic enzyme (proteinase K etc.). For the specific staining of rabies virus antigen by 
immunohistochemical testing, the primary anti-rabies serum, anti-species serum, and the 
peroxidase complex are used (Bourgon and Charlton, 1987; Sinchaisri et al., 1992). 
Latex agglutination test (LAT) is a simple and rapid technique, which may be used 
more widely in the laboratory diagnosis of rabies in the future. It has been used to detect 
rabies virus antigens in the saliva of dogs with 99% specificity and 95% sensitivity. The 
essence of the LAT is inducing agglutination on a glass slide using polystyrene latex 
beads coated with anti rabies IgG (Kasempimolporn et al., 2000, 2007). 
 
1.4.2. Detection of viral genome 
The reverse transcriptase polymerase chain reaction (RT-PCR) with subsequent 
nucleotide sequencing permits the diagnosis of rabies, typing, and molecular 
epidemiological studies. Since the rabies genome is RNA, the amplification procedure 
consists of the reverse transcription of the target RNA strain into complimentary DNA  
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(cDNA), followed by the amplification of the cDNA by PCR (Tordo et al., 1995, 1996). 
The RT-PCR procedure consists of the following steps: total RNA extraction, 
cDNA synthesis with random or specific primers, amplification of the cDNA with specific 
primers, and visualization of the results with horizontal electrophoresis in agarose gel 
containing ethidium bromide observed under UV light (Heaton et al., 1999). 
 The RT-PCR is widely used for rabies diagnosis, and different parts of the genome 
can be targeted for this reason, but in most cases the N gene is utilized (Kulonen and 
Boldina, 1993; Bourhy et al., 1999; Ito et al., 2003; Losa-Rubio et al., 2005). A rapid RT-
PCR technique was developed for the detection of the classical rabies virus (genotype 1) 
and the rabies related EBLVs (genotypes 5 and 6), and also to distinguish between the 
six established rabies and rabies-related virus genotypes (Black et al., 2000, 2002). The 
PCR can also be applied to detect the rabies virus genome in formalin-fixed paraffin-
embedded brain tissue (Kulonen et al., 1999) and for the intravitam diagnosis of rabies in 
humans by testing saliva and cerebrospinal fluid (Crepin et al., 1998). The Real-time 
PCR is a quantitative technique which allows the detection of an increase in the amount 
of DNA (cDNA) during amplification. It is currently used for the ante- and post-mortem 
diagnosis of rabies and the discrimination of the Lyssavirus genotypes (Wakeley et al., 
2005; Nagaraj et al., 2006; Saengseesom et al., 2007). 
 
1.4.3. Virus isolation 
 The mouse inoculation test (MIT) was one of the first diagnostic tests for rabies. 
Laboratory mice are inoculated intracerebrally or subcutaneously with the supernatant of 
the sample suspension. The inoculated mice must be observed for up to 30 days after 
inoculation. Death during the first 48 hours after inoculation must be considered as non-
specific; all the animals dead after this period must be dissected and brain samples must 
be tested for rabies by the FAT (Koprowski, 1996). This method can be used for testing 
the brain and salivary gland suspensions, as well as the saliva samples, for the presence 
of live rabies virus (Adeiga and Audu, 1996; Delpietro et al., 2001). 
The cell culture inoculation test has already replaced the MIT in many countries 
and implies the isolation of rabies virus in a cell culture monolayer with visualization by 
the FAT. A number of cell lines have been selected and tested: cow brain cells (CB3), 
cerebral and cerebellar grey matter cells of mice (MBC-2, MBC-3), chicken embryo 
fibroblasts (CEF), murine, feline and human glial cultures, human monocytic U937 and 
THP-1 cells, murine macrophage IC-21, murine monocytic WEHI-3BD- and PU5-1R  
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cells, murine monocytic P388D1 and J774A.1 cells, kidney epithelial cells derived from 
African green monkey (Vero), and McCoy cells (Smith et al., 1978; Clark, 1980; Celer et 
al., 1991; Ray et al., 1995, 1997; Nogueira, 2004). Tollis et al., (1988) compared the 
sensitivity of the murine neuroblastoma (MNA), baby hamster kidney (BHK-21), and the 
canine fibrosarcoma A-72 cells, and confirmed that the MNA cells are the most sensitive 
to infection with the wild strains of the rabies virus. MNA cells are currently widely used 
for field virus isolation and a method employing this cell culture is recommended by the 
WHO and the OIE (Webster et al., 1996, OIE, 2004). 
 
1.4.4. Detection of virus neutralizing antibodies 
 The detection of anti-rabies virus neutralizing antibodies (VNA) is widely used to 
evaluate the potency of anti-rabies vaccines because the minimal level of the VNA 
needed to protect animals against rabies has been determined as ≥ 0.5 IU/ml (OIE, 
2004). 
Virus neutralization assay has also been found useful for the monitoring of 
Lyssaviruses among bats (Arguin et al., 2002; Lumlertdacha et al., 2005). 
Virus neutralization in mice or cell cultures. The determination of the VNA was 
previously conducted by virus neutralization in mice (Atanasiu, 1973) and subsequently 
replaced by the fluorescent antibody virus neutralization (FAVN) or rapid fluorescent 
focus inhibition testing (RFFIT) (Thomas, 1975; Zalan et al., 1979; Smith et al., 1996; 
Cliquet et al., 1998). This method enables the determination of antibody levels by the 
neutralization of a known dose of the rabies virus (commonly the CVS strain). Serum 
samples are tested and compared with the neutralization of reference standard serum 
with an antibody level of 0.5 or 1.0 IU/ml. This test can be conducted on microplates and 
the results viewed with fluorescence microscopy. The registration of the results can be 
automated by various means: by using an inverted fluorescence microscope coupled with 
a video camera and color image analysis software computer system (Peharpre et al., 
1999); a peroxidase conjugate can be used instead of the fluorescent conjugate, and in 
this case an automatic multi-channel spectrophotometer can be used for the registration 
of the results (Hostnik, 2000a); flow cytometry method for calculating anti-rabies VNA has 
also automated results registration (Bordignon et al., 2002). 
 ELISA can also be used to determine antibody levels in serum samples 
(Kasempimolporn et al., 2007). 
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This method can be used for assessing the efficacy of oral fox vaccination campaigns 
and it was demonstrated that by using commercial ready-to-use microplates sensitized 
with rabies virus glycoprotein, a simple and rapid ELISA technique enables the obtaining 
of a rabies antibody quantization in field fox serum samples (Mebatsion et al., 1989; 
Esterhuysen et al., 1995; Cliquet et al., 2000, 2003, 2004, 2007; Servat et al., 2007). 
 The latex agglutination test is also used to detect rabies-specific antibodies. Latex 
beads are sensitized by coating them with purified rabies glycoprotein to detect anti-
glycoprotein antibodies in serum samples. The visible agglutination is observed in the 
positive sera with a titer ≥ 2 IU/ml within 3–5 min after mixing, while serum samples 
containing less than 2 IU/ml do not agglutinate (Madhusudana and Saraswati, 2003). 
 
1.5. Rabies epidemiology 
1.5.1. Rabies situation world-wide 
Rabies is widely distributed throughout the world and is present in all continents 
except Australia, where only bat Lyssavirus has been found, and in Antarctica. 
Worldwide, it has been estimated that approximately 55000 persons die annually due to 
rabies; 99% of human rabies deaths have occurred in the developing countries. The total 
global expenditure on rabies prevention is well over US$ 1 billion annually (Warrel et al., 
1995; WHO Expert Consultation on Rabies, 2005). 
Different animal species can be responsible for viral circulation and rabies 
transmission in different continents and countries. Canids have been determined to be 
the main hosts of the rabies virus in Africa; in most cases they are also responsible for 
the transmission of the virus to humans. In addition to canids (domestic and wild dogs, 
jackals, and wolves), mongooses, and bats are involved in rabies epidemics, as occurs in 
Africa (Adeiga et al., 1996; Bingham, 2005). Dogs are also the primary reservoir for 
rabies in Thailand (Tepsumethanon et al., 2005). In the USA, several species are 
involved in rabies epidemics but the main reservoirs are raccoons and skunks (Krebs et 
al., 2003). An epizootic of raccoon rabies, begun in the USA in the late 1970s, and 
developed into one of the largest and most extensive in the history of wildlife rabies 
(Childs et al., 2000). Rabies has been detected in rodents and lagomorphs, mostly in 
woodchucks (Childs et al., 1997) and also in arctic foxes (Ballard et al., 2001). In 
addition, bats are sometimes responsible for the transmission of rabies to humans (Miah, 
2005). 
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1.5.2. Rabies situation in Europe and in Russia 
Foxes and raccoon dogs are considered to be the most susceptible species in 
Europe (Artois, 1992; Kihm et al., 1992; Gylys et al., 1998). According to rabies data for 
the years 2005 and 2006, there were 13 rabies-free countries in Europe: Belgium, the 
Czech Republic, Cyprus, Finland, Greece, Iceland, Italy, Ireland, Luxembourg, Norway, 
Portugal, Sweden, Switzerland, and Lichtenstein. With 9,830 cases of rabies (including 9 
human and 35 bat cases) in 2005, the total number of cases of rabies in Europe 
(European countries and European parts of Russia) has increased by 80% when 
compared with 2004 to approximately similar level as that of 2003. This increase is based 
on a 2 to 2.3-fold higher reporting of rabies cases from Russia and Ukraine (Rabies 
Bulletin Europe, 2005). A similar tendency was observed in Turkey, where dog-mediated 
rabies is the main problem (Rabies Bulletin Europe, 2005; Johnson et al., 2006; Kilic et 
al., 2006). Finland is a rabies-free country but three imported rabies cases were recorded 
recently. In 2003 rabies was found in a horse imported from Estonia (Metlin et al., 2006); 
in 2007a human case was recorded in a Philippine male working on a cruise ship (Kallio-
Kokko H., personal communication); later in the same year, another rabies case occurred 
in a pappy imported from India (communication of the Ministry of Agriculture and Forestry 
of Finland). 
Wild animals, manly red fox, are still the main rabies hosts in Europe. In 2006, 
9172 rabies cases were reported in Europe, 6152 of these occurred in wild animals, 2984 
in domestic animals, and only 34 in bats. In addition, 2 human rabies cases were 
reported (Rabies Bulletin Europe, 2006). 
Rabies is endemic in the Baltic countries; in 2006, 114 animal rabies cases were 
recorded in Estonia, 472 in Latvia, and 2232 cases in Lithuania. The number of rabies 
cases in animals from Estonia decreased in 2006 by 57% when compared with 2005. 
This may be due to the oral wildlife vaccination started in Estonia during 2005 (Niin et al., 
2007). In Latvia and Lithuania, an increase in the number of animal rabies cases was 
recorded in 2006 compared with 2005 (an increase of about 10% in Latvia and 
approximately 26% in Lithuania (Rabies Bulletin Europe, 2006). 
Rabies is a very serious veterinary and public health problem in the Russian 
Federation. The disease is widespread throughout the country (Fig. 5) and affects 
different animal species: farm animals (mainly cattle, pigs, sheep, goats, and horses), 
domestic pet animals (predominantly dogs and cats), and wild animals (red foxes,  
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raccoon dogs, badgers, wolves, lynx, etc.). The disease is enzootic in Russia and there is 
an increasing tendency in the number of rabies affected territories (Dudnikov, 2003b); 
also almost 10 human rabies cases are reported annually. 
 
Figure 5. Map of the Russian Federation and bordering countries. The Russian 
regions affected by rabies (according to data recorded in 2006) are colored dark grey. 
 
The largest outbreaks of rabies have occurred in the south-western regions of the 
Russian Federation and rabies is spreading further to the northern and eastern directions 
(Makarov and Vorob’ev, 2004). The number of animal rabies cases increased annually 
from 2000 to 2005, except for 2004, when a decrease in rabies cases was recorded (Fig. 
6). In 2006, the number of animal rabies cases decreased substantially (approximately 
57%). 
 
Figure 6. Dynamics of the number of animal rabies cases (total for all species) in 
Russia during the last 8 years. 
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It is well established that the main reservoirs of the rabies virus in the Russian 
Federation are wild carnivores. These animals are very susceptible to rabies, intensively 
excrete virus with saliva, are inclined to long and distant migrations, are aggressive and, 
in addition, have a high population density. These factors in combination with the 
elevated rate of generation change and relatively long incubation period assure the 
continuous epidemic process despite the fatality of infection. Foxes are considered to be 
the main wild vector of rabies in Russia, followed by raccoon dogs (Sidorov et al., 2004). 
Raccoon dogs have been introduced to the European part of the former Soviet Union in 
the 1930-1940, and became an important vector for rabies in Russian. The first cases of 
rabies in these animals were recorded during the winter of 1931-1932 and the first case 
of human rabies after being bitten by a raccoon dog occurred in 1951 (Botvinkin et al., 
1981). 
The existing situation with regards to rabies diagnosis within the regions of the 
Russian Federation does not allow any conclusions to be drawn relative to the 
dissemination of rabies, and therefore systematic monitoring is needed (Dudnikov, 
2003a). 
 
1.5.3. Models of rabies epidemics 
 Understanding the interaction between ecological dynamics, spatial spread, and 
evolutionary changes in infectious diseases is important, and will help in the interpretation 
of epidemiological patterns and provide a basis for constructing a predictive theory of 
disease emergence (Grenfell et al., 2004). The Kendall’s threshold theorem (Kendall, 
1957) states that an epidemic will occur if the contact between infective and susceptible 
individuals is as such that each infected individual, on average, meets and infects more 
than one susceptible individual. If this happens, the disease frequency begins to increase 
exponentially, if not – it declines exponentially. In reality, the exponential changes do not 
persist for a long period because the number of susceptible individuals becomes limited 
and there are consequent changes in the rate of contact (Bacon and Macdonald, 1980). 
 To predict local and spatial dynamics of the epizootics of rabies, mathematical 
models have been developed and are now widely used in rabies epidemiology. These 
models are based on population density, recorded data of rabies cases, landscape 
particularities, etc. (Moore, 1999; Childs et al., 2000; Smith et al., 2002; Russell et al., 
2005). A simulation model was used by Thulke et al. (1999) to study the spatio-temporal  
  
25
dynamics of a potential rabies outbreak in an immunized fox population after the 
termination of a long-term, large-scale vaccination programme with two campaigns per 
year: one in spring and the other in autumn. The use of integrated approaches, such as 
the geographical analysis of sequence variants, coupled with information on spatial 
dynamics is an indispensable aid to understand the patterns of disease emergence (Real 
et al., 2005). 
 
1.6. Fixed strains of rabies virus 
1.6.1. Laboratory strains 
 Two laboratory strains, the CVS (Challenge/Control Virus Strain) and PMPV 
(Pitman-Moore Pasteur Virus), are widely used. Both strains are considered to be 
derivates of the original Pasteur virus strain (Smith et al., 1993). The CVS strain has two 
stable variants: CVS-B2c and CVS-N2c, these differ in pathogenicity for healthy mice and 
in the capacity to affect neurons (Morimoto et al., 1999). These laboratory strains are 
used in different diagnostic tests such as the virus neutralization and focus inhibition 
tests, as well as for the potency testing of anti-rabies vaccines in laboratory animals. 
 
1.6.2. Vaccine strains and anti-rabies vaccines 
Since the first rabies vaccination in 1885 by Louis Pasteur (Pasteur, 1885), 
significant progress has been made in improving the pre- and post-exposure treatment of 
human rabies (Dietzschold et al., 2003). There are several types of vaccines: live 
attenuated, inactivated (killed), DNA-based, and vector vaccines. For the production of 
anti-rabies vaccines, a number of attenuated vaccine strains are employed: the Pasteur 
Virus (PV), Evelyn Rokitniki Abelseth (ERA), Street-Alabama-Dufferin (SAD), 3aG, 
Fuenzalida S-51 and S-91, Ni-Ce, SRV9, PM, Nishigahara, RC-HL, Kelev, Flury, 
“Shelkovo-51”, “O-73 Uz-VGNKI”, “RV-71”, “Krasnopresnenskii-85”, and the RV-97 strain 
(Steck et al., 1982; Fodor et al., 1994; Gruzdev and Nedosekov, 2001; Ito et al., 2001b; 
Borisov et al., 2002). The PV is one of the first vaccine strains; it was isolated from a 
rabid cow in 1882 and attenuated by multiple passages in rabbits. The SAD strain was 
isolated from a rabid dog in Alabama (USA) in 1935 and adapted for cultivation in the 
mouse brain and in the baby hamster kidney cell culture. It has two main derivates: ERA 
and Vnukovo-32. Several variants of the SAD strain exist: SAD-Berne, SAD B19, SAD-
P5/88 etc., and also non-virulent mutants SAG-1 and SAG-2. The vaccine strains 
belonging to the SAD group are widely used throughout the world. One of the most  
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widely used oral anti-rabies vaccines is prepared from the SAD B19 strain, the high 
immunogenicity and relative safety of this strain has been demonstrated experimentally 
(Vos et al., 2000; Neubert et al., 2001). 
Live attenuated vaccines are still in use in some developing countries for 
parenteral vaccination of animals and humans. These contain live attenuated rabies virus 
which has been developed in cell cultures or in live animals such as sheep. In the 
developed world, live attenuated vaccines are only used for the oral immunization of wild 
animals. Oral vaccines are widely used and several vaccine strains are used for the 
production of such vaccines: the SAD B19 and other SAD-strains, SAG1 and SAG2 – 
apathogenic deletion mutants, Vnukovo-32, and the VRG strain (Brohier et al., 1991; Vos 
et al., 2000). The vaccine strain RV-97 is used in Russia for producing the oral anti-rabies 
vaccine “Sinrab”. This strain was obtained in the FGI “Federal Centre for Animal Health” 
(Vladimir, Russia) from strain RB-71. The ancestor to these two strains is the strain 
“Sheep”, derived from the PV strain. The strain “Moscow” is also believed to be a 
derivate of the PV strain (Gruzdev and Nedosekov, 2001), and was used in the former 
USSR for producing anti-rabies vaccine. The strain RV-97 is adapted for cultivation in cell 
culture BHK-21 (Borisov et al., 2002). 
 Inactivated vaccines. Complete inactivated rabies virus particles are highly 
immunogenic. The vaccines based on this principle are used for the pre- and post-
exposure immunization of humans and domestic animals (Dietzschold et al., 2003). The 
inactivated chicken embryo vaccines and vaccines based on virus cultivated in cell 
cultures are used for veterinary and medical purposes (Sihvonen et al., 1993, 1994, 
1995; Briggs et al., 1996; Benjavongkulchai et al., 1997). Modern medical vaccines can 
be administered by the intradermal route (WHO, 1995; Dressen, 1997; WHO, 1997). 
 DNA vaccines are based on plasmid vectors expressing rabies virus glycoprotein. 
These vaccines have been tested for their efficiency in several animal species (mice, 
dogs and nonhuman primates), and it has been found that the DNA vaccine develops 
VNA levels and offers protection comparable with those obtained with the inactivated 
vaccines (Ray et al., 1997; Wang et al., 1998; Bahloul et al., 1998; Perrin et al., 1999; 
Lodmell, 1999; Osorio et al., 1999; Lodmell et al., 2000, 2001, 2002). On the basis of the 
results of the study conducted in mice, a single administration of the rabies DNA vaccine 
may be as effective as at least five injections of the cell-culture-derived vaccine (Bahloul 
et al., 2003). 
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 Vector vaccines are based on recombinant viruses, and several viruses have been 
tested for these purposes. The VRG vaccine was designed on the basis of poxvirus 
(vaccinia virus) expressing SAD strain glycoprotein and used for oral immunization of 
wildlife (Wiktor et al., 1984; Brochier et al., 1990, 1991; Winkler et al., 1992; Meslin et al., 
1994). The Adrab.gp - vaccine is based on the adenovirus expressing the ERA strain 
glycoprotein and was found capable of inducing an immune response in dogs (Tims et 
al., 2000). The canine herpesvirus (CHV) expressing the glycoprotein of rabies virus has 
also been used successfully as an anti-rabies vaccine (Xuan et al., 1998). A raccoon 
poxvirus (RCNV) recombinant vaccine for the immunization against feline panleukopenia 
and rabies has been developed and tested in cats (Hu et al., 1997). A recombinant rabies 
virus vaccine carrying two identical glycoprotein (G) genes (SPBNGA-GA) has also been 
constructed (Faber et al., 2002). 
 The rabies virus vaccine strain based on vectors have shown great promise as 
vaccines against other viral diseases such as human immunodeficiency virus type 1 
(HIV-1) infection and hepatitis C, but a low residual pathogenicity remains a concern for 
their usage (McGettigan et al., 2003). 
Plant-derived antigens can also be used for the immunization against rabies. The 
coat protein of alfalfa mosaic virus has been used as a carrier molecule to express the 
antigenic peptides from rabies virus. The in vitro transcripts of the recombinant virus with 
sequences encoding the antigenic peptides have been synthesized from DNA constructs 
and used to inoculate tobacco plants. The plant-produced protein (virus particles) has 
been purified and used for the immunization of mice, and specific anti-rabies virus-
neutralizing antibodies in immunized mice have been found (Yusibov et al., 1997; 
Modelska et al., 1998); spinach has also been used for this purpose (Koprowski, 2002). 
The transgenic maize expressing the G protein of the Vnukovo strain has also been 
obtained and tested in mice. It was shown that the mice developed virus neutralizing 
antibodies which were able to provide protection of 100% against the challenge of a 
vampire bat strain (Loza-Rubio et al., 2007). 
Oral vaccination of wildlife against rabies. Before the era of oral vaccines, the only 
feasible measure for controlling rabies in wildlife was the depopulation of reservoir 
species (Aubert, 1994); but currently rabies is the only zoonosis that can be controlled by 
the oral vaccination of wildlife. The idea of conducting active immunization of wildlife 
appeared in the last century (Baer, 1975), but many difficulties, such as the form of the 
vaccine, methods of distribution and uptake control, and possible residual pathogenicity  
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have to be surpassed. Since then, several laboratory and field trials have been 
conducted (Wandeler et al., 1988), and different delivery methods including vaccine traps 
and wool getters were designed (Winkler and Bogel, 1992; Matter et al., 1998). Initially, 
plastic vessels containing the vaccine were attached to chicken heads (Steck et al., 
1982), but recently different types of modern vaccine baits and different meal mixtures for 
producing these were developed and tested (Linhart et al., 1997). The vaccine based on 
the strain SAD B19 is one of the most widely used in Europe: 70 million vaccine baits 
were used between 1983 and 1988 (Vos et al., 2000). Studies on the immunogenicity 
and efficacy of the SAD B19 attenuated rabies virus vaccine in foxes were conducted 
under laboratory conditions (Neubert et al., 2001). 
Vos et al. (1999) studied the safety of the SAD B19 vaccine in 16 animal species 
by different administration routes; a low residual pathogenicity was observed only for 
certain rodent species, but transmission of the vaccine virus to control animals was not 
demonstrable, since no vaccine virus was detected in the saliva of the six mammal 
species examined. Furthermore, the genetic stability of the SAD B19 vaccine was shown 
through passage in neural tissue of dogs, foxes, and mice. From those results presented 
here on the innocuity and stability, it can be concluded that the SAD B19 rabies vaccine 
is suitable for the oral vaccination campaigns of carnivores against rabies (Vos et al., 
1999). Nevertheless, several rabies cases have been caused by live attenuated viruses 
(Pastoret et al., 1999; Wandeler, 2000), so the development of new, safer vaccine strains 
is a very important issue. 
Two mutant vaccine strains were obtained by directed mutagenesis of the strain 
SAD. The SAG-1 contains one nucleotide substitution, while the SAG-2 has two 
substitutions at amino-acid position 333 of the rabies virus glycoprotein (Follmann et al., 
1996). These vaccine strains are apathogenic for adult mice inoculated by the 
intracerebral route (Flamand et al., 1993). The SAG-2 based vaccine was demonstrated 
as a safe and effective vaccine for the oral immunization of canines (Fekadu et al., 1996; 
Masson et al., 1996; Bingham et al., 1997, 1999; Lambot et al., 2001). 
The vector-based VRG vaccine is another candidate for the oral application to 
immunize wild carnivores. The pathogenicity of a vaccinia recombinant virus expressing 
the rabies glycoprotein was tested with the red fox, wild boar, Eurasian badger, different 
species of mice and voles, common buzzard, kestrel, carrion crow, magpie, and jay. 
During the observation period, the 107 animals given the vaccine orally did not show any 
clinical signs (Brochier et al., 1988, 1989). Experiments have demonstrated the efficacy  
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of a vaccinia-rabies recombinant virus administered by the oral route in foxes. Because of 
its safety and heat-stability, this recombinant virus could be an excellent alternative to the 
attenuated strains of rabies virus currently used in the field (Brochier et al., 1990, 1991, 
1996; Desmettre et al., 1990; Lambot et al., 2001). The high thermo stability of the 
commercially produced Raboral VRG bait allows its use during the summer for 
emergency vaccination campaigns (Masson et al., 1999), and is being used for the 
vaccination of wild raccoons in the USA (Olson et al., 2000). The VRG vaccine has also 
been tested as an oral vaccine in vampire bats and significant protection was observed in 
animals vaccinated 18-30 days before challenge (Setien et al., 1998). 
Oral vaccination of wild animals has been successfully conducted in many 
countries: such as Austria, Croatia, Switzerland, Italy, Germany, Slovenia, Czech 
Republic, Slovakia, Israel, USA, Canada, Belgium, France, etc. (Steck et al., 1982; 
Westerling, 1989; Gram, 1996; Separovic, 1996; Schluter, 1996; Svrcek et al., 1996; 
Matouch, 1996; Mutinelli, 1996; Linhart et al., 1997; Olson et al., 1999, 2000; Hostnik, 
2000b; MacInnes et al., 2001). The sylvatic rabies epidemic of 1988-1989 was 
successfully eradicated in Finland by the oral immunization of wild carnivores (Nyberg et 
al., 1992), and was also used in some areas of Russia. One of these vaccination areas is 
located at the Finnish-Russian border within the Leningrad region and the Republic of 
Karelia. The oral vaccination was organized in 2003 within the framework of the 
international Finnish-Russian collaboration program for controlling rabies in wildlife, and 
financially supported by the EU and the Finnish government (Metlin et al., in press). 
The most common strategy for conducting oral vaccination campaigns is to use 
vaccine baits at a density of approximately 25 baits per square km, twice a year, during 
the spring and autumn, to avoid the negative influence of temperature on vaccine baits 
and to reach adult foxes (in spring) and juvenile foxes before they disperse (in autumn) 
(Aubert et al., 1994; Vos, 2003). However, further studies on the population dynamics of 
the red fox, the onset and progress of the reproductive season, and maternal immunity 
and the immune response of fox cubs to oral vaccination have shown that it was 
necessary to optimize the old strategy and conduct two spring vaccinations: first in 
March, and then before the end of May to cover young foxes (Muller et al., 1999, 2001; 
Vos et al., 2001). 
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There are two ways of distributing vaccine baits in nature: manually and by air 
(helicopters, airplanes). Presently, aerial distribution is widely used and special computer 
models have been developed to plan the distribution of vaccine baits taking into account 
many factors including landscape and terrain details (Thulke et al., 2004). 
 
1.7. Molecular biology of rabies viruses 
1.7.1. Antigenic characterization with monoclonal antibodies 
 The first mAbs of the rabies virus were obtained in 1978 (Wiktor et al., 1978). 
Study of rabies virus isolates with mAb directed against particular viral proteins allows 
antigenic characterization of the virus being evaluated and, in many cases, strain and 
serotype differentiation (Mebatsion et al., 1992; Delpietro et al., 1997; Nadin-Davis et al., 
2000; Okoh, 2000). 
 With the help of mAbs directed against the different viral proteins, their antigenic 
and functional properties have been determined. Luo et al. (1998) studied the rabies virus 
glycoprotein with a panel of 35 mAbs and concluded that the G protein forms a complete 
antigenic structure with conformational-depended antigenic sites and epitopes. Goto et 
al. (2000) have used mAbs to map antigenic epitopes and to analyze the structure of the 
nucleoprotein antigenic sites. 
Monoclonal antibodies were also used in Finland during the last sylvatic rabies 
outbreak. All the viruses isolated were studied using a panel of three mAbs (W-239, W-
187.5, and P-41), and all induced positive reactions indicating the persistence of the 
Arctic antigenic variant of the rabies virus. Later, using the same panel of mAbs, 24 
rabies samples collected from Estonia between 1989 and 1992 were studied; two 
different Arctic variants were found, one of these having the same characteristics as the 
Finnish isolates, the other demonstrated a unique (W-187.5 – negative) reaction 
(Kulonen et al., 1993). 
The three mAbs mentioned above have been included in more extensive panels 
(up to 20 mAbs) and were used for the characterization of rabies viruses isolated in 
Europe (Cox et al., 1992) and different parts of the African continent (Umoh et al., 1990; 
Mebatsion et al., 1992). A wide range of different groups of rabies viruses was found in 
these studies. 
Several panels of mAbs, of different origins, have been applied during the last two 
decades in Russia. In 1983, Selimov et al. have studied 39 rabies virus strains using a 
panel of 4 monoclonal antibodies; later on this work was continued and 271 field rabies  
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virus isolates were studied with a mAb P-41 (Selimov et al. 1983, 1994). Gribencha et al. 
(1989) developed a panel of 7 anti-nucleocapsid and 3 anti-glycoprotein mAbs, and these 
have demonstrated that individual variants of the rabies virus can be detected using this 
panel. Botvinkin et al. (1990) applied a panel of 39 mAbs to characterize 98 rabies 
viruses, which resulted in several diverse reaction patterns indicating that different 
antigen variants were found during those studies. In 1991, Gribencha et al. have 
published research studies aimed at obtaining a panel of mAbs to characterize 
antigenically the vaccine strain Vnukovo-32 and to compare its antigenic properties with 
the field rabies viruses (Gribencha et al., 1991a, b). Botvinkin et al. (2006) applied a wide 
panel of 74 mAbs and compared the results obtained with phylogenetic data, where it 
was demonstrated that the results of the antigenic studies are often in concordance to 
those of genetic studies. 
 
1.7.2. Genetic characterization of rabies virus 
According to the WHO Expert Consultation on Rabies (2005) it is important to 
conduct molecular characterization of the new field isolates of the rabies virus. Several 
phylogenetic and molecular-epidemiological studies on rabies have been performed 
during the past 10 years (Smith et al., 1992; Kissi et al., 1995; Bourhy et al., 1999, Nadin-
Davis et al., 1999; Holmes et al., 2002; Kuzmin et al., 2004, Real et al., 2005). These 
studies have shown that the rabies viruses can be divided into two major groups, one 
comprising viruses isolated from terrestrial mammals and the other containing viruses 
isolated from bats or spillover infections from bats. 
Additionally, there is a viral lineage that is closely related to the bat rabies virus but 
which circulates independently in raccoons and skunks, suggesting that it might 
represent a secondary transmission from bats. It was also found that among terrestrial 
mammals, rabies viruses cluster more by geographical origin than by host species, and in 
this case, closely related viruses infect a variety of species (Davis et al., 2006). The 
phylogenetic reconstruction strongly supports the hypothesis that host switching has 
occurred in the history of the Lyssaviruses. It has been proven that the Lyssaviruses 
have evolved in chiropters long before the emergence of the carnivoran rabies, probably 
due to spillovers from bats (Badrane and Tordo, 2001). The rabies virus is an ancient 
virus but it has been suggested that the current diversities in the genotype 1 of the 
Lyssaviruses from diverse geographical locations and different species may have started 
only within the last 500 years (Holmes et al., 2002). 
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The RT-PCR amplification, nucleotide sequencing of the different genome regions, 
and the subsequent genetic and phylogenetic analysis allows the determination of the 
genetic groups and the differentiation of the field and vaccine strains of the rabies virus. 
Different genome regions can be and have been used in molecular-epidemiological 
studies of the rabies virus. The G gene and the G-L intergenic region (pseudogene, ψ-
region) are much more variable than the N gene and evolutionary pressure on individual 
protein coding genes within the genome varies considerably (Johnson et al., 2002a). The 
pseudogene region has been used for the genetic characterization of rabies viruses in 
several studies (Bourhy et al., 1999; Hyun et al., 2005; Nel et al., 2005). The analysis of 
the sequence of the nucleoprotein is considered to be adequate for reliable phylogenetic 
study of the rabies virus, and the additional glycoprotein gene sequence analysis is 
important for the characterization of antigenic and immunogenic properties of the virus 
(Kasempimolporn et al., 2004; Kuzmin et al., 2004). 
During the last century, rabies virus was spreading to the West and South of 
Europe but natural barriers, such as the Vistula River in Poland, were able to limit its 
dissemination (Bourhy et al., 1999). Bourhy et al., (1999) have classified rabies viruses of 
European origin into four main groups: the NEE-group (North-East Europe), the EE-group 
(East Europe), the WE-group (Western Europe), and the CE-group (Central Europe). 
Recently, Kuzmin et al. (2004) studied a wide range of rabies viruses isolated from the 
territory of the former Soviet Union and classified these into five genogroups (A, B, C, D, 
and E). The data from that study have shown that the viruses with the same geographical 
origin often group together during phylogenetic analyses. The number of rabies virus 
variants is co-circulating in Europe, and are often associated with the red fox; also there 
are dog-associated rabies and the role of raccoon dogs in maintaining rabies in the Baltic 
countries is increasing (McElhinney et al., 2006). Mansfield et al. (2006) have 
demonstrated the existence of two groups within the general Arctic group: “Arctic 1” and 
“Arctic 2”, the latter having two subgroups and a separate “Arctic-like” group. The study of 
isolates from countries in the Middle East has shown the existence of few closely related 
groups which are different from the viruses of European and African origin; no host-
dependent relations were found in this study (David et al., 2000). A molecular study of 
Brazilian rabies viruses has shown the presence of three main host-specific groups, 
especially among bat viruses and victims of vampire bats (Bernardi et al., 2005). Some 
authors have combined the use of mAbs and molecular methods to study the 
characteristics of rabies viruses (Mebatsion et al., 1993; De Mattos et al., 1996, 1999;  
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Nadin-Davis et al., 2001, 2003; Favoretto et al., 2002). 
Most of the rabies cases in terrestrial animals and human beings are due to the 
genotype 1 viruses, but some cases are caused by viruses from other genotypes. Spill-
over of the EBLV1 virus into the stone marten (Martes foina) under natural conditions has 
been recorded in Germany (Muller et al., 2004). Also in 1998 cases of rabies in sheep 
that were shown to have been infected with the EBLV-1a possibly derived from 
insectivorous bats were observed in Denmark (Stougaard and Ammendrup, 1998), and in 
2002, a second occurrence of the EBLV-type 1 in sheep was reported (Ronsholt, 2002). 
Also, several human cases caused by EBLVs and ABLV strains have been reported in 
some European countries and in Australia (Lumio et al., 1986; McColl et al., 2000; Fooks 
et al., 2003; Spooner, 2003). 
One of the most important issues in the field of rabies research is the identification 
and characterization of new genotypes. Due to PCR and nucleotide sequencing during 
the last ten years, one new genotype has been identified and four additional were 
proposed. Fraser et al. (1996) isolated a new Lyssavirus from bats in Australia, which was 
later identified by nucleotide sequencing as the new seventh genotype: Australian bat 
Lyssavirus or ABLV (Gould et al., 1998). The phylogenetic analysis of the ABLV viruses 
has shown that they form a monophyletic group distinct from the other Lyssaviruses, and 
two antigenic variants of ABLV were described (Guyatt et al., 2003). Arai et al., (2003) 
studied rabies virus isolated from the Lesser Mouse-eared Bat (Myotis blythi) in 
Kyrgyzstan and have suggested that it belonged to a new genotype of the rabies virus 
(Aravan virus). Furthermore, the Khujand virus isolated from northern Tajikistan in 2001 
can be classified as a separate genotype of Lyssavirus (Kuzmin et al., 2003). Two unique 
viruses (Irkut and West Caucasian) have been isolated from bats in Russia and based on 
genetic studies it has been suggested that they belong to new genotypes (Botvinkin et al., 
2003; Kuzmin et al., 2005). 
 
1.7.3. Entire genome sequencing of vaccine strains 
The entire genome sequencing of the vaccine strains provides important data 
relative to the rabies virus genome and allows its antigenic, genetic, and immunogenic 
properties to be predicted and analyzed. To conduct complete sequencing of the rabies 
virus genome, several techniques can be employed. Tordo et al. (1986, 1988) used 
cloning in plasmid vector pBR322 and sequence determination by the chain-terminating 
inhibitor method after inserting endonuclease restriction fragments of the cDNA inserts  
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into the M13 vectors. Conzelmann et al. (1990) employed the ligation of the synthetic 
oligonucleotide to the genomic RNA of the SAD B19 vaccine strain, after which the 
cDNAs obtained were ligated again with the EcoRI adaptor, and cloned into the λgt 10 
phages. Ito et al. (2001b) sequenced the RT-PCR products of 13 fragments, covering 
almost the full-length of the viral genome to obtain the entire genome sequence of the 
vaccine strain RC-HL. The ligation of the synthetic SSON adaptor with T4 RNA ligase to 
the ends of the genomic and antigenomic RNAs was employed to obtain the 3’- and 5’- 
terminal noncoding regions. The PCR-amplified DNAs were then used for cloning. 
The entire genome sequences of all the rabies virus vaccine strains, which are 
more or less used worldwide, have been determined and published in international 
databases. Nevertheless, the entire genome sequences of the field rabies viruses are not 
as common as those of vaccine strains; very few of these being currently available in 
public databases. 
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2. Aims of the study 
 
The scope of the present study covers the genetic characterization of the field and 
attenuated rabies viruses and the molecular-epidemiological study of rabies in Finland 
and Russia. To accomplish this, the following goals had to be attained: 
 
1. The collection of field rabies viruses from different regions of the 
Russian Federation, especially in the North-Western regions; 
 
2. The development of an RT-PCR technique for rabies diagnosis and 
scientific purposes; 
 
3. The antigenic and genetic characterization of the field rabies viruses 
from Russia, Finland (archival samples), and of the vaccine strains that 
are used in Russia and Finland; 
 
4. The phylogenetic and molecular epidemiological analyses of the 
obtained data; 
 
5. The entire genome sequencing, and antigenic and genetic 
characterization of the Russian vaccine strain RV-97 used for the oral 
immunization of wildlife against rabies. 
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3. Materials and methods 
 
3.1. Field rabies virus isolates 
Brain samples of rabid, wild, domestic/pet, and farm animals were collected from 
the different administrative regions of the Russian Federation (including the North-
Western, Western, Southern, Caucasian, Central, and Siberian regions), Finland (archive 
viruses and one imported case), and Estonia (archival viruses) (papers I, II, III and IV). 
Initially, 113 brain samples from rabid animals of different species were collected 
from the 11 regions of the Russian Federation (paper I). This study was later continued, 
and collectively 233 rabies brain samples from the 17 Russian regions, Finland, and 
Estonia were analyzed (paper II, unpublished results). The Russian regions close to 
Finland and those regions with an elevated number of recorded rabies cases were given 
preference during the collection of isolates. Six archival samples collected from Finland 
during 1988-1989 and in 2003 (imported case, paper III), and 5 samples collected from 
Estonia in 1991 (paper I) were included in this study. 
 
3.2. Vaccine and laboratory strains 
Two Russian vaccine strains were included in this study (RV-97 and “Sheep”): the 
strain RV-97 has been propagated in the baby hamster kidney cells. This strain is widely 
used in Russia for the production of the commercial live attenuated oral anti-rabies 
vaccine intended for the immunization of wild carnivores, known as “Sinrab”, FGI 
“Federal Centre for Animal Health”, Vladimir, and Russia (FGI “ARRIAH”). The Strain RV-
97 is known to be a derivate of the strain “Sheep”, which was previously used for 
producing brain anti-rabies vaccines (paper V). 
The rabies virus strain CVS-11 (ATCC VR 959) was used in the monoclonal 
antibody (mAb) characterization tests and in virus neutralization tests as a positive 
control. 
 
3.3. Cell cultures 
The murine neuroblastoma cell culture (MNA) was used for the isolation of the 
field rabies viruses (papers I, II, III, and IV), and the baby hamster kidney cell culture 
clone C13 BHK-21 was used for the cultivation of the vaccine strains (paper V). 
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3.4. Monoclonal antibodies 
A panel of five murine anti-nucleocapsid mAbs (W-239.17, W-187.5, W-187.11.2, 
MW-187.6.1, and P-41) produced in the Federal Research Centre for Virus Diseases of 
Animals, Tuebingen, Germany, was used to study the antigenic characteristics of the field 
rabies viruses and vaccine strains (Cox et al., 1992) (papers I and II). 
 
3.5. Laboratory techniques 
3.5.1. Fluorescent antibody test 
The protocols of standard techniques were used to perform the direct and indirect 
FAT (Dean et al., 1996; Smith and King, 1996). The fluorescent antibody and cell culture 
inoculation tests were performed using the rabies anti-nucleocapsid conjugate (BioRad, 
France), polyclonal rabbit anti-rabies FITC-immunoglobulin “ARRIAH” (FGI “ARRIAH”), 
and the monoclonal FITC-conjugate Centocor (Centocor Inc, USA). The rabbit anti-
mouse FITC-conjugated antibodies (DAKO, Denmark) were used as secondary 
antibodies during the indirect FAT. 
To prepare smears, glass slides and wooden sticks were used. After fixation in 
acetone at 
-20°C for at least 1h, the smears were stained with the diagnostic FITC-conjugates or 
mAbs in a humid chamber for 30 minutes at 37°C, washed for 10 minutes in phosphate 
buffered saline (PBS Dulbecco A, OXOID), pH 7.3, and then during 5 minutes in distilled 
water. The slides stained with mAbs were dried, stained with anti-mouse FITC-
immunoglobulin, and rewashed as described above. After drying at room temperature, 
one drop of 50% glycerol in PBS was added to each smear and the slides were covered 
with cover-slips. The smears stained only with the anti-mouse FITC-conjugate were used 
as negative controls. 
 
3.5.2. Cell culture inoculation test 
The cell culture inoculation test was performed according to the OIE Manual 
(2004) with slight modifications (Kulonen et al., 1993). After preparation of 10% (w/v) 
brain suspension and centrifugation at 1000 g, the supernatants were filtered using 
disposable plastic syringe filters (“Schleicher & Schull” FP 30/0.45 CA-S). For virus 
isolation, 1.0 ml of the filtered supernatant was mixed with 1.0 ml MNA cell suspension at 
the concentration of 106 cells/ml in Eagle’s minimum essential medium (MEM) with 10% 
fetal bovine serum. Diethylaminoethyl-dextran (DEAE-dextran, Sigma®, mol. wt. 500 000)  
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was added to all mixtures and these were then incubated at 37°C for 30 minutes, with 
shaking every 10 minutes and centrifuged. The cell pellet obtained was resuspended in 
4.0 ml of MEM and mixed with 9.0 ml of the same medium. From the volume obtained, 
6.0 ml were divided into 6 wells of a 24-well tissue culture plate (Nunclon®, Denmark) and 
7.0 ml were placed in 25-cm2 plastic culture flasks (Nunclon®, Denmark). 
The plates and flasks were incubated at 37°C in 5% CO2 atmosphere for 4 days. 
After incubation, the flasks were frozen, thawed to destroy the cells, and the liquid 
obtained was used for the next passages. At least two passages were made before 
staining, but in some instances more (up to 6) were done. The plates were stained with 
polyclonal FITC-conjugates ARRIAH and mAbs. A similar suspension made from the 
brain of a healthy dog was used as the negative control. 
 For the staining of the cell-culture plates, the culture medium was removed from 
the wells and 1.0 ml of 80% acetone was added to each well. The plates were incubated 
at 4°C for 30 minutes, the acetone was then removed and 0.2 ml of the FITC-conjugate 
or mAbs was added to the appropriate wells. The plates were incubated at 37°C for 30 
minutes, washed with PBS for 10 minutes and then with distilled water for another 5 
minutes. The FITC-conjugated rabbit anti-mouse immunoglobulin was added to the wells 
stained with mAbs, and incubation and washing were carried out as described above. 
 
3.5.3. Reverse-transcriptase polymerase chain reaction 
The total RNA for RT-PCR was isolated from cell-culture or brain suspensions 
using the “RNeasy Mini Kit” (QIAGEN®, Great Britain). The cDNA synthesis, using 5 µl of 
purified total RNA as a template, was carried out with the MuLV-reverse transcriptase 
and the 5 pmol of Random Hexamers primer (Applied Biosystems) at 37°C for 90 minutes 
in a volume of 20 µl. 
Two primer pairs were designed for more detailed estimation of molecular-
biological characteristics by PCR: the first pair (N-primers) amplifies the N-gene segment 
of 380 base pairs (nt 626-986), and the second pair (G-primers) 280 nucleotides (4835-
5095) covering the end of the G-gene and partially the G-L intergenic region (paper II). 
The numbering of the nucleotides is according to the SAD B19 sequence (Conzelmann et 
al., 1990). 
All PCR reactions were carried out in a volume of 50 µl. The mixtures included 5 µl 
of 10-fold buffer for DNA polymerase, 5 pmol of each primer, 1 U Dynazyme II of DNA 
polymerase (Finnzymes), and 1 µl 10 mM of dNTP’s. Thirty-five cycles of template  
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denaturation at 94°C for 1 minute, primer annealing at 55°C for 1 minute, and 
polymerization at 72°C for 1 minute were done. The products were run in 2% agarose gel 
and results were visualized using ethidium bromide (papers II, III, and IV). 
 
3.5.4. Nucleotide sequencing 
Before sequencing, the PCR products were purified by using the “MicroSpin S-
400HR” columns (Amersham Pharmacia Biotech, USA). The BigDye Terminator Cycle 
Sequencing kit was used according to the manufacturer’s instructions; the sequencing 
run was carried out using the 16-capillary sequencer ABI3100 Genetic Analyzer (Applied 
Biosystems, Foster City, CA, USA) at the Institute of Biotechnology, University of 
Helsinki, and at the Evira Virology Unit. The sequencing results were edited by using the 
Staden Package v.2003.0-beta (Staden et al., 2000). 
 
3.5.5. Entire genome sequencing of the vaccine strain RV-97 
The RV-97 strain used herein was obtained from the live, attenuated, oral anti-
rabies vaccine intended for the immunization of wild carnivores (“Sinrab”, FGI “ARRIAH”). 
After 1 passage in BHK-21 cell culture (clone C13), the strain was used for further 
genetic studies. The entire genome sequence of the vaccine strain RV-97 was obtained 
by joining 16 fragments (Fig. 7). The 3’- and 5’- termini of the genome were also obtained 
using the universal primer END_Oligo (paper V). 
 
Figure 7. Schematic location of the primer pairs within the viral genome. 
Designations on the figure: N – nucleoprotein; P – phosphoprotein; M – matrix 
protein; G – glycoprotein; L – RNA-dependent RNA polymerase; Ψ – G-L 
intergenic region (pseudogene). 
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The total RNA was purified from the virus-infected cell culture suspension by using 
the “RNeasy Mini Kit” (QIAGEN®, cat no. 74104). The cDNA synthesis and RT-PCR were 
performed, as described in paper II, with R-primers listed in table 1 or with Random 
Hexamers primer (Applied Biosystems). The only difference is that polymerisation was 
carried out for 1.5 min. To amplify the 3’- and 5’- terminal non-coding regions, the primers 
1R and 12F were used to obtain the cDNAs. Further, the RT-PCR was conducted with 
the primers 1R and 12F and an “END_Oligo” synthetic adaptor. 
The technique for obtaining the 3’- and 5’- terminal non-coding regions is based on 
the reverse complementarity of the first 11 nucleotide bases at both ends of the rabies 
virus genome (Fauquet et al., 2005). The use of the END_oligo primer does not make it 
possible to evaluate the sequence of 11 nucleotide 3’- and 5’- terminals, which are 
considered to be conserved even between rabies and rabies-related viruses (Bourhy et 
al., 1989). The first 11 nucleotides at the 3’- and 5’- terminals were also conserved in all 
the sequences used for the phylogenetic analysis during this study, and it was presumed 
that the RV-97 strain contains the same sequences. 
The RT-PCR products obtained were purified by using the “MicroSpin S-400HR” 
columns (Amersham Pharmacia Biotech, USA). The purified products were sequenced 
with the same primers that were used for the PCR (Table 1 in paper V). A BigDye 
Terminator Cycle Sequencing kit was used for the sequence reactions according to the 
manufacturer’s instructions; the sequencing was carried out using the 16-capillary 
sequencer ABI3100 Genetic Analyser (Applied Biosystems, Foster City, CA, USA). The 
sequences were assembled by using the Staden Package v. 2003.0-beta by joining 16 
fragments including the non-coding 3’- and 5’- ends of genome (Staden et al., 2000). 
 
3.6. Phylogenetic analysis 
The phylogenetic analyses were performed by using the MEGA Version 3.1 
program (Kumar et al., 2004). For the field rabies viruses, the minimum evolution 
phylogenetic trees were constructed and bootstrapped with 1000 replicates. The 
neighbor-joining phylogenetic trees were also built using the Kimura-2 parameter. In 
addition to the field strains, six rabies vaccine strains were included in the phylogenetic 
analysis. The sequences obtained in this study were compared with a wide variety of 
sequences published in the Gene Bank database, after which representatives of the 
genogroups created were used to construct the final phylogenetic trees. The rabies virus 
isolated from a bat in Colorado was used as the out-group (papers III and IV). 
  
41
The entire genome sequence of the Russian vaccine strain RV-97 was aligned 
with 10 entire genome sequences of vaccine the strains obtained from the Gene Bank 
database. For phylogenetic analysis, the nucleotide sequences of the 5 viral genes of 
each strain were translated into protein sequences and joined to one sequence in the 
original order. The bat virus SHBRV-18 was taken as an out-group and the minimum 
evolution phylogenetic tree was rooted to this virus. The phylogenetic tree was 
bootstrapped with 1000 replicates (paper V). 
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4. Results 
4.1. FAT and cell culture inoculation test 
All samples tested by the diagnostic FAT were rabies positive. The samples were 
further analyzed with indirect FAT on glass slides (field viruses from the Russian 
Federation) or in cell cultures (archival viruses from Finland and Estonia and vaccine 
strains). In some cases, cell culture inoculation tests and RT-PCR and nucleotide 
sequencing were conducted; these results were also positive. 
 
4.2. Antigenic characteristics of field rabies viruses (papers I, II and III) 
Five antigenic variants were found among the 233 virus samples tested by means 
of the reaction pattern with the panel of mAbs (Table 1). 
 
Table 1. Antigenic variants of rabies virus isolates using mAbs 
Reaction with Mab Antigenic 
variant/Region 
Genot
ype W-239.17 W-187.5 W-187.11.2 MW-
187.6.1 
P-41 
The results of this study 
I. Bryansk, Estonia, 
Finland, Kursk, Pskov, 
Tver 
+ + + + + 
II. Estonia + - + + + 
III. Bashkiriya, Belgorod, 
Bryansk, Krasnodar, 
Kursk, Mordoviya, 
Novosibirsk, 
N.Novgorod, Orel, 
Penza, Tver, Vladimir, 
Voronezh 
+ + + + - 
IV. Bashkiriya, Krasnodar,
Mordoviya, Moscow, N.
Novgorod, Ryazan, Tver,
Tula, Vladimir 
+ - + + - 
V. Tver, Moscow 
1 
+ - + - - 
Results from the literature 
Arctic1 1 + + + + + 
European fox2 1 + + + + - 
West-European2 1 + - + + - 
Logos bat3, 4 2 + - - + - 
Mocola3, 4 3 + - - + - 
Duvenhage3, 4 4 + - - + - 
EBL12 5 + - - - - 
EBL21 6 + - - + - 
1 Schneider et al., 1985; 2 Cox et al., 1992; 3 Umoh et al., 1990; 4 Mebatsion et al., 1992. 
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The antigenic variant I seem to correspond to the Arctic antigenic variant, while the 
antigenic variants III and IV corresponded to the European fox and West-European 
antigenic variants, respectively (Cox et al., 1992). The antigenic variants II and V did not 
correspond to any of the previously found variants. 
The antigenic variant I circulates mainly in the North-Western regions of Russia, 
Finland, and Estonia (see map, paper I). The antigenic variant II was isolated only from 
the Estonian islands (Kulonen et al., 1993), and the antigenic variants III and IV from the 
Central and South-Western regions of Russia. The antigenic variant V was isolated from 
the Tver and Moscow regions of the Russian Federation (papers I and II). 
The fixed rabies virus strains can be divided into two groups according to their 
reaction pattern with these five mAbs: SAD B19 belongs to the antigenic group V and 
RV-97, «Sheep» and CVS-11 strains belong to the antigenic group III. 
 
4.3. Development of RT-PCR tests (papers II and III) 
The RT-PCR that was developed is based on the amplification of two distant 
regions of rabies virus genome: a fragment of the nucleoprotein gene and the G-L 
intergenic region. Field rabies viruses selected on the basis of the reaction patterns with 
mAbs and the vaccine strains SAD B19, CVS-11, RV-97, and «Sheep» were successfully 
amplified with the N- and G-primer pairs, producing bands of the expected sizes (Fig 8). 
The RT-PCR products were suitable for further automated nucleotide sequencing. 
 
 
Figure 8. RT-PCR electrophoresis picture. Field rabies virus Tver-96 (line 1 N and 
G) and vaccine strain RV-97 (line 2 N and G). k- - negative control, М - marker. 
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4.4. Phylogenetic analysis and molecular epidemiology (papers III and IV) 
Among the field viruses, two major phylogenetic groups, the Pan-Eurasian and 
Caucasian, were observed (Fig. 9). The Pan-Eurasian group was further divided into four 
separate subgroups. Three of them: the Eurasian, North European, and Central Russian 
subgroups were observed during this study. The fourth subgroup includes some 
European viruses classified as members of the West Europe (WE) and Central Europe 
(CE) groups by Bourhy et al. (1999). According to the N-gene sequence analysis, the 
nucleotide differences within these groups were approximately 2% and 4-7% between 
subgroups. 
 
 
Figure 9. Minimum evolution phylogenetic tree. Phylogenetic relations of the two 
major genogroups and 7 vaccine strains (Metlin et al. in press). Reference sequences 
included: Tordo et al., 1986; Conzelmann et al., 1990, Bourhy et al., 1999; Ito et al., 
2001b; Nadin-Davis et al., 2003 ; Kuzmin et al., 2004. 
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The “Eurasian” group comprises viruses from the European, Central, Asian, and 
Siberian parts of Russia, as well as from Kazakhstan (Fig. 10, paper IV). The “North-
European” group contains viruses from Finland and Estonia, as well as from the Pskov, 
Bryansk, and the Leningrad regions of Russia. The viruses from the geographically close 
Moscow, Vladimir, Tver, and Tula regions constitute a separate “Central-Russian” group. 
A similar grouping was found based on the G-L intergenic region sequences. Additionally, 
the phylogenetical groups in most cases corresponded to antigenic variants as revealed 
by the mAbs. 
 
Figure 10. Geographical distribution of the rabies viruses groups observed during 
this study. N-E – North-European Group (includes archival viruses from Finland, Estonia, 
and Leningrad region), Eurasian – Eurasian group, C-R – Central-Russian group, Cau – 
Caucasian group (framed). Lakes, rivers, gulfs, seas, and oceans are light blue. Arm – 
Armenia; Azr – Azerbaijan; Czh – Czech Republic; Est – Estonia; Geo – Georgia; Lth – 
Lithuania; Lva – Latvia; Mld – Moldova; Rom – Romania; Svk – Slovakia; Uzb – 
Uzbekistan. 
 
The viruses isolated from the Southern part of the Krasnodar region near the 
Georgian border and Black Sea coast comprise the “Caucasian” group. They are closely 
related to the viruses from Georgia and Iran (paper IV). The viruses from the Caucasian  
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group differ from those observed in the Pan-Eurasian group by 6-7% according to the N-
gene sequences, and by approximately 9% based on the G-L-intergenic region 
sequences. 
According to both the N- and G-L-intergenic region sequences, all the vaccine 
strains evaluated (paper IV) clearly differed from the field strains and the Russian vaccine 
strains “Sheep” and RV-97 grouped together with the vaccine strains of Japanese origin 
Ni-Ce, RC_HL, and Nishigahara. The viruses from the Caucasian phylogroup seem to be 
the closest wild ancestor of this group (Fig. 9). 
A wide range of classical rabies viruses was included in the phylogenetic analysis 
when the origin of the equine strain RV1904 isolated in Finland during 2003 in a horse 
imported from Estonia was investigated, this virus was found to be similar to the viruses 
previously isolated from Russia and the Baltic region. The clinical course of the disease 
was also described (paper III). 
To summarize the phylogenetic grouping, we put together and compared the 
classifications by Bourhy et al. (1999) and Kuzmin et al. (2004), and the classification 
used during this study (paper IV) (Table 2). 
 
Table 2. Comparison of three different phylogenetic classifications for rabies 
viruses isolated in the Eurasian continent 
Classifications Origin of viruses 
Bourhy et al., (1999) Kuzmin et al., 
(2004) 
This study 
Yakutia, Tuva, 
Krasnoyarsk (Russia) --- A --- 
Far East of Russia --- B --- 
Kazakhstan, Central, 
Siberian and South 
parts of Russia 
--- C Eurasian 
Central and Western 
regions of Russia 
9215HON, Hungary, 
ungrouped D 
Central-
Russian 
North-Western and 
Western Russia, 
Finland, Estonia, 
Slovakia, Poland 
North-Eastern 
Europe (NEE) E 
North-
European 
E
urasian phylogroup 
Western Eastern and 
Central Europe 
Western Europe 
(WE), Eastern 
Europe (EE) and 
Central Europe (CE) 
--- --- 
Caucuses of Russia, 
Georgia, Iran --- UG Caucasian 
*The overlapping groupings are shadowed. 
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It was obvious that the phylogroups proposed by different research groups 
overlapped in many cases, but alternatively, they supplemented each other. Some 
ungrouped viruses may further be classified as members of a distinct group during further 
research. 
 
4.5. Entire genome sequencing and characterization of RV-97 strain 
(paper V) 
The entire genome sequence of the RV-97 strain obtained was 11932 nt in length. 
Among vaccine strains, 4 different phylogroups can be found and this division is 
supported by the high bootstrap values (96-100). The Russian vaccine strain RV-97 
forms a separate branch and seem to be more related to the Japanese group of vaccine 
strains (Nishigahara etc.) (Fig. 11), since it shares 92-93% nucleotide sequence identity 
and 95% amino-acid sequence identity with the Japanese group. The identity of the 
nucleotide and amino-acid sequences of the RV-97 strain with two other groups of 
vaccine strains (SAD/PV and American strains) is 89-90% and 94%, respectively; with 
the bat strain SHBRV-18 (out-group), the nucleotide and amino-acid identities were 80% 
and 91%, respectively. 
 
Figure 11. Minimum evolution phylogenetic tree. The phylogenetic relations of 11 
vaccine strains. GeneBank accession numbers: Ni-Ce - AB128149, Nishigahara - 
AB044824, RC-HL - AB009663, PV - M13215, SAD B19 - M31046, SRV9 - AF499686, 
ERA - EF206707, Hep-Flury - AB085828, Lep-Flury - DQ099524, PM1503 - DQ099525, 
RV-97 - EF542830. The tree was rooted to the out-group strain SHBRV-18 - AY705373. 
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The vaccine strains RV-97 and SAD B19 were further compared at the amino acid 
level with other vaccine strains (Table 3). 
 
Table 3. Comparison of some antigenic/immunodominant sites/epitopes of 11 
vaccine strains 
Strains* Amino acid sequence structure 
Nucleoprotein, AG site I (374-383). 
RV-97, Ni_CE, Nishigahara, RC_HL, LEP_Flury, 
HEP_Flury, SAD B19, SRV9, ERA, PV,  LTKTDVALAD 
PM1503 LTKTEMALAD 
Nucleoprotein, antigenic site III (313-337) 
RV-97, SAD B19, SRV9, PV, PM1503 LEP_Flury, 
HEP_Flury, ERA HFVGCYMGQVRSLNATVIAACAPHE 
Ni_CE, Nishigahara, RC_HL HFVGCYMGQIRSLNATVIAACAPHE 
Nucleoprotein, Immunodominant 404_418 
RV-97, Ni_CE, Nishigahara, RC_HL AVYARIMMNGGRLKR 
SAD B19, SRV9, ERA, LEP_Flury, HEP_Flury, PM1503 AVYTRIMMNGGRLKR 
PV AVYTRIIMNGGRLKR 
Two antigenic sites of phosphoprotein in position 75-90 
RV-97, PV, ERA, SRV9, SAD B19 GKYREDFQMDEGEDPS 
LEP_Flury GKYREDFQMDEGEDPN 
HEP_Flury GKYREDFQMNEGEDPN 
PM1503 GKYREDFQMGEGEDPN 
Ni_CE GRHQEDPQMDEGEDPS 
Nishigahara, RC_HL GRHQEDFQMDEGEDPS 
Immunodominant cytotoxic T epitope of phosphoprotein in position 191-206 
RV-97 EEDDLSAEAEITHQIA 
LEP_Flury, SAD B19, SRV9, PV, PM1503, Ni_CE, 
Nishigahara, RC_HL EEDDLSVEAEIAHQIA 
HEP_Flury GEDDLSVEAEIAHQIA 
ERA EKDDLSVEAEIAHQIA 
Structure of antigenic epitope I of Glycoprotein in position 231 
RV-97, LEP_Flury, HEP_Flury, PM1503, Ni_CE, 
Nishigahara, RC_HL, ERA, SADB19, SRV9, PV L 
Antigenic site II of Glycoprotein in position 34-42 and 198-200 
RV-97, HEP_Flury, ERA, Ni_CE, Nishigahara, PV, SAD 
B19 GCTNLSGFS KRA 
LEP_Flury, PM1503 GCTNLSEFS KRA 
RC_HL GCTNLSGFS KRV 
SRV9 ECTNLSGFS KRA 
Antigenic site III of Glycoprotein in position 330-338 
RV-97, LEP_Flury, PM1503, Ni_CE, Nishigahara, RC_HL, 
ERA, SAD B19, PV KSVRTWNEI 
HEP_Flury KSVQTWNEI 
SRV9 KSVSTWNEV 
Antigenic epitope VI of Glycoprotein in position 264 
RV-97, LEP_Flury H 
HEP_Flury, PM1503, Ni_CE, Nishigahara, RC_HL, ERA, 
SAD B19, SRV9, PV R 
Antigenic site “a” of Glycoprotein at position 342-343 
RV-97, LEP_Flury, HEP_Flury, PM1503, Ni_CE, 
Nishigahara, RC_HL, ERA, SAD B19, SRV9, PV KG 
 
  
49
The analysis of the structure of the immunodominant 404-418 epitope of the 
nucleoprotein shows that the RV-97 strain is different by 1 amino acid from the strain 
SAD B19. The structure of immunodominant cytotoxic T epitope of the phosphoprotein at 
position 191-206 of RV-97 seems to be unique and different from the structures of the 
other vaccine strains by at least two amino acids. 
Because the glycoprotein is the major antigen of the rabies virus, we analyzed the 
major immunodominant site mapped at position 222-332 of the mature glycoprotein 
(Johnson et al., 2002b). The structure of the antigenic epitope I within the framework of 
the major immunodominant site is conserved among the vaccine strains (paper V). The 
antigenic epitope VI is different from the RV-97 strain and most of the other vaccine 
strains. Furthermore, part of the antigenic site III seems to be conserved among the 
vaccine strains, only two of them; SRV9 and HEP_Flury, having different amino acids at 
position 333, serine and glutamine, respectively. All the other strains have arginine at this 
pathogenicity-dependent position. There are three sites of complete differences between 
the strain RV-97 and other strains: serine at position 222 in RV-97 and alanine at all other 
strains, serine in RV-97 at position 253 and proline in all the others, and isoleucine at 
position 318 in RV-97 and phenylalanine in all the others. 
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5. Discussion 
Rabies is a serious veterinary and public health problem in Russia and in some 
bordering countries. Finland was declared rabies-free in 1991. Since the last outbreak of 
rabies in 1988-1989, the spread of this disease has been prevented by vaccinating cats 
and dogs, and by the oral immunization of wild carnivores covering the region of 
Finland’s south-eastern border with Russia (Nyberg et al., 1992). Since then, three 
imported rabies cases were recorded in this country (horse, in 2003, human and dog in 
2007 (paper III; Kallio-Kokko H., personal communication; communication of the Ministry 
of Agriculture and Forestry of Finland). Because rabies is an important problem for both 
Finland and Russia, the Finnish-Russian collaboration on rabies control was started and 
all the studies described herein were conducted within frames of this collaboration. 
The monoclonal antibodies allow the detection of the antigenic variants and, in 
many cases, the typing of rabies virus strains. Over the last 20 years, several panels of 
mAbs have been used in Russia (Selimov et al., 1983; Gribencha et al., 1989; Botvinkin 
et al., 1990). This study covers several regions of Russia, as well as Finland and Estonia. 
More than 200 rabies virus isolates were collected for typing by using a panel of 5 
antinucleocapsid mAbs. The Russian regions, adjacent to Finland and regions having a 
high number of recorded rabies cases were given preference for the collection of isolates. 
The monoclonal antibodies used in our experiment have been used over the last decade 
for the antigenic characterization of Lyssaviruses of European and African origin 
(Schneider et al., 1985; Umoh et al., 1990; Cox et al., 1992; Mebatsion et al., 1992). 
 Five different antigenic variants of rabies virus isolates have been identified. The 
isolates reacted in the same manner as the Arctic antigenic variants isolated within the 
Russian Federation, Finland, Estonia, and Norway (Schneider et al., 1985; Kulonen and 
Boldina, 1993). The variant “II”, originally isolated by Kulonen and Boldina (1993), has 
been tested with a more extensive panel of antinucleocapsid mAbs. A previously 
unknown rabies virus type was isolated from foxes in the Tver Region (Staritsky district) 
and in the Moscow region of the Russian Federation (papers I and II and unpublished 
results). Some fixed rabies viruses such as the SAD, ERA etc. show the same reaction 
pattern (Cox et al., 1992). 
The antigenic variant IV was found to be prevalent in the central regions of Russia 
and the antigenic variant III was predominant within the South-Western regions. The 
antigenic variant I was found mostly in the North-Western regions of Russia as well as in  
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Estonia and Finland, but also in the Kursk and Bryansk regions located in the Western 
part of Russia. The unique antigenic variant V was only found in the Tver and Moscow 
regions, located in the central part of Russia, where several rabies virus types were 
isolated. 
A positive reaction with the P-41 mAb was considered to be the main 
characteristic of the Arctic antigenic variant. During the last sylvatic rabies epidemic in 
Finland, only the Arctic antigenic variant was found. The same virus type exists in 
continental Estonia as well as in the Pskov, Tver, Kursk, and Bryansk regions of the 
Russian Federation. The Pskov and Tver regions are adjacent to Estonia, but a very 
pronounced mixture of different rabies virus types was found only in the Tver Region. 
Selimov et al. (1994) have identified P-41 positive isolates collected from Estonia, 
Belarus (the Minsk region), the Leningrad, Pskov, Kaliningrad regions, and the Kola 
Peninsula (the Murmansk region) during 1969-1991. 
It was found, that the Russian vaccine strain RV-97 demonstrated similar reaction 
pattern to the mAbs to the antigenic variant III, while the SAD B19 strain reacted similarly 
to the antigenic variant V. 
Unfortunately, the panel of mAbs used in this study could not be used to 
differentiate between the field viruses belonging to the antigenic variants III and V from 
the vaccine strains RV-97 and SAD B19; other techniques would have had to be 
employed for this purpose. 
At present, the PCR and nucleotide sequencing are more widely used for the 
molecular studying of rabies viruses than monoclonal antibodies. The PCR developed in 
this study is in use at Evira for diagnostic purpose, and also a laboratorial ante mortem 
diagnosis was made with the aid of this technique (human case imported from Philippines 
to Finland in 2007). In this study, the groupings obtained with the monoclonal antibodies 
in many cases correlated with the phylogenetic grouping. The nucleotide sequences 
obtained during this study have been deposited in the public database Gene Bank. 
Finland was declared rabies-free since 1991, but in 2003 a case of rabies in an 
imported horse was recorded. There has been a considerable amount of exportation and 
importation of horses between Estonia and Finland, and between Russia and Finland, but 
cases of imported rabies have not been previously diagnosed in Finland. The incubation 
period of the rabies virus can vary considerably from a few days to several months or 
even years (Baer 1991). Rabies in horses must always be differentiated from other 
infectious diseases, such as pseudo rabies (Aujeszky’s disease), listeriosis etc., as well 
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as from non-infectious diseases (e.g., colic and intoxication). The occurrence of this 
disease in an animal imported from a rabies-affected country is highly suggestive of an 
imported case of rabies. The monoclonal antibody characterization of the equine virus 
RV1904 showed a reaction pattern typical of the Arctic viruses. The Arctic viruses are 
very common in Estonia and some Western regions of Russia, where rabies is endemic 
in wild and domestic animals. The virus isolated from this horse was genetically 
characterized and was found to be a either member of the North-East European group 
(NEE) (Bourhy et al., 1999) or the E group (Kuzmin et al., 2004), which are clearly 
overlapping. Presently, the Finnish Ministry of Agriculture and Forestry recommends that 
horses traveling to and from a rabies-affected area should be vaccinated. Imported dogs 
and cats have to be certified to show that they have developed ≥0.5 IU/ml anti-rabies 
virus-neutralizing antibodies (Regulation No 998/2003/EC, OIE, 2004). This antibody 
level is considered to be adequate to protect the animal against rabies infection. Thus, 
quarantine of animals with an unknown vaccination status would be a valuable measure 
in preventing the introduction of rabies. 
The molecular epidemiological studies help to localize the origin of a virus and 
make it possible to develop rabies control programs, and prevent the introduction of the 
rabies infection into rabies-free areas. Two main phylogenetic groups were established 
among the field viruses studied: Pan-Eurasian and Caucasian. The general Pan-Eurasian 
group comprised four subgroups, designated as the Eurasian, North-European, and 
Central-Russian subgroups, which corresponded to the phylogenetic groups C, D, and E 
published by Kuzmin et al. (2004), but the WE/CE group of Bourhy et al. (1999) did not 
overlap with any of these groups. In our studies we prefer the usage of geographical 
nomenclature as it is more informative and gives key features of basic geographical 
locations of the phylogenetic group (Table 2). 
The Eurasian subgroup comprises viruses from Siberia (Novosibirsk) to the 
Western (Belgorod) and South-Western (Krasnodar) regions of the Russian Federation. 
The viruses from Omsk, Altai (Russia), and Kazakhstan, previously classified by Kuzmin 
et al. (2004) as members of group C, also belong to this group. This group seems to be 
the most widespread in Russia (Fig. 10, paper IV). 
The viruses from the North-European group were positive for the P-41 mAb, 
indicating the Arctic antigenic group origin. The North-European group includes viruses 
from Finland and Estonia, in addition to the Pskov, Bryansk, and Leningrad regions. It is  
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clear that viruses circulating in Estonia and the Pskov region of Russia are very similar. 
Previous antigenic and genetic studies have confirmed that the isolates 
responsible for the Finnish outbreak (1988-1989) were related, but not identical to the 
viruses isolated from the Baltic region (Kulonen et al., 1993; Bourhy et al., 1999; Johnson 
and Fooks, 2005). It may be suggested that rabies has gradually moved from the 
Russian/Estonian territories after prolonged circulation among local hosts before being 
detected. The causative agents included in this study belong to the North-European 
group, which corresponds to the group E of Kuzmin et al. (2004) and to the group NEE of 
Bourhy et al. (1999). 
Several explanations, such as animal-to-animal transfer, human-mediated transfer 
(e.g., by railways), or the movement of infected animals across the frozen sea have been 
suggested (Johnson and Fooks, 2005). We report a close phylogenetic relationship 
among viruses isolated from Finland during the period 1988-1989 and in 2003, Estonia 
between 1989 and 1990, the Leningrad region (Russia) in 1990, and from the Pskov 
region (Russia) in 2002. Two ways of transmission seem to be more probable: gradual 
animal-to-animal terrestrial movement via/from the Leningrad region or across the frozen 
surface of the Gulf of Finland directly from the Estonian territory. The last explanation 
seems to be more probable because most cases were found on the Western side of the 
Kymi River and one case was found on an island on the southern rim of the coastal ice 
(Nyberg et al., 1992). Rabies could still be reintroduced into Finland by imported animals, 
as occurred in 2003 and in 2007, but due to the annual oral vaccination campaigns on 
both sides of Russia’s south-eastern border with Finland, the development of major 
sylvatic epidemic in south-eastern Finland seems unlikely. 
The Central-Russian group comprises viruses mostly from the Central part of 
Russia and seems to overlap with group D of Kuzmin et al. (2004). The viruses from 
these regions clearly differ even from those isolated from the bordering regions, such as 
the N. Novgorod region. The Oka and Volga rivers are considered as limiting factors for 
virus circulation, by separating Moscow and Vladimir and parts of the Ryazan and Tver 
regions from the other regions. Rivers significantly limit the extensive movement of wild 
carnivores and allow the independent evolution of viruses in distinct regions. During the 
last century, some barriers, such as the Vistula River in Poland, were able to restrict the 
spread of rabies from Eastern to Western and Southern Europe (Bourhy et al., 1999). 
However, this barrier is not absolute and animals can easily cross rivers in several ways 
(across the ice in winter when the water is frozen, over bridges, or by swimming).  
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Nevertheless, the major rivers remain an important limiting factor for the development of 
rabies epidemics and this must be taken into account when anti-rabies programs, 
especially oral-vaccination campaigns are being developed. 
The mountains are also capable of limiting the circulation of the rabies virus. In our 
study, viruses from the north-western part of the Krasnodar region were clearly different 
from those viruses isolated in the area located on the other side of the Caucasian 
Mountains, near the border of Georgia. This area is separated from the rest of the 
territory in the Krasnodar region by the Caucasian Mountain Range. Some viruses from 
Iran (Nadin-Davis et al., 2003) and from Georgia (Kuzmin et al., 2004) belong to this 
phylogroup. 
All the field viruses studied herein clearly differed from the vaccine strains, and 
also from the 96_2002 virus that was isolated in the Tver region and had a mAb reaction 
pattern similar to some vaccine strains of the SAD group. The oral vaccination of wild 
carnivores with different types of live-attenuated vaccines has been conducted in that 
region so that the recombination between field and vaccine strains can be theoretically 
possible. Although the recombination rate of the Lyssavirus is low, there are data 
suggesting that this may occur (Chare et al., 2003). The Russian, Estonian, and Finnish 
field rabies viruses and the Russian vaccine virus strains were analyzed phylogenetically 
on the basis of two distant genome regions, and basically the grouping of viruses was 
similar in both regions; these results provide no evidence to support the idea that the 
recombination between field viruses and vaccine strains occurred. However, these 
findings indicate that the vaccines used in the region were stable and did not revert back 
to their native pathogenic form. 
A specific host for the phylogenetic groups could not be clearly defined during this 
study because the virus members of the phylogroups that were determined were found in 
both wild and domestic/farm animals. However, the viruses from the North-European 
group are mostly maintained in red foxes and raccoon dogs (Nyberg et al., 1992; Bourhy 
et al., 1999; Johnson and Fooks, 2005), and are transmitted to domestic and farm 
animals. The Caucasian phylogenetic group may also be associated with dogs, but 
further studies have to be conducted to support this statement. 
The entire genome sequence analysis allows characterization of the genetic 
properties and phylogenetic relations at a very reliable level. It is especially important for 
the strains used for the production of oral anti-rabies live attenuated vaccines, because 
several rabies cases caused by such vaccines in wildlife have been reported (Pastoret  
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and Brochier, 1999). The vaccine strain SAD B19 is widely used for the production of live 
attenuated vaccines in Europe for the immunization of wild carnivores against rabies 
(Artois, 1992; Vos et al., 2000; Neubert et al., 2001). In Russia, the vaccine strain RV-97 
is used for the production of anti-rabies vaccine for wild animals (Borisov et al., 2002). 
Several techniques have been previously used by different research groups for the 
entire sequencing of rabies virus genome: cloning into plasmid vector (PV strain, Tordo et 
al., 1986), cloning in λgt 10 phages (SAD B19 strain, Conzelmann et al., 1990), 
sequencing RT-PCR products, and ligation of synthetic adaptor to obtain 3’- and 5’- 
terminal non-coding regions (RC-HL strain, Ito et al., 2001b). In this study, we used a 
technique similar to the methods described by Ito et al. (2001b) and by Bouhy et al. 
(1989). Sixteen overlapping fragments of the genome were obtained with RT-PCR, and 
subjected to automated sequencing. The technique for obtaining the 3’- and 5’- terminal 
non-coding regions is proposes using the universal synthetic adaptor “END_Oligo” for 
both ends in combination with the first reverse and last forward primers using the RT-
PCR technique to obtain the 3’- and 5’-termini. The inverse complementarity of the first 
10 nucleotide bases at both ends (Virus Taxonomy, 2005) of the rabies virus genome 
allows this simple and fast technique to be used. Unfortunately, the use of the END_oligo 
primer does not make it possible to evaluate the sequence of 11 nucleotides at the 3’- 
and 5’- terminals, which are considered to be conserved even between rabies and rabies-
related viruses (Bourhy et al., 1989). The first 11 nucleotides at the 3’- and 5’- terminals 
are also conserved in all the sequences used for phylogenetic analysis during this study, 
and it was presumed that the RV-97 strain contains the same sequences. 
 The vaccine strain RV-97 was found not to be a member of well-known 
phylogenetic groups, such as the SAD/PV (SAD B19, PV, etc.), American (Hep/Lep-
Flury, PM) or the Japanese (Nishigahara, RC-HL and Ni_Ce) groups, but it was more 
closely related to the last one of these. It was assumed that the Russian rabies virus 
vaccine strain RV-97 originates from the PV-strain (PV→ “Sheep” → RB-71 → RV-97; 
Gruzdev and Nedosekov, 2001), but this seems unlikely on the basis of data obtained 
from this study. Also another derivate of the PV strain, – “Moscow”, was used in the 
former USSR for the production of anti-rabies vaccines. The analysis of additional 
Russian strains could be of value when searching for the nearest common ancestor of 
the Japanese vaccine strains and the RV-97 strain. 
 Most of the amino acid differences found in this study are located outside the 
mapped antigenic and immunodominant regions. However, six of the eight known  
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antigenic sites (epitopes) of the G protein are conformational, and any amino acid 
changes within close proximity to these epitopes could potentially affect the folding of the 
protein (Tordo, 1996). 
Two amino acid differences were found at positions 197 (alanine in RV-97, valine 
in the SAD B19) and 202 (threonine in RV-97, alanine in SAD B19) inside the 
immunodominant cytotoxic T epitope of the P protein. The structure of the two antigenic 
sites of the P protein is identical for the RV-97 and SAD B19 strains, but the RV-97 strain 
has a unique structure of the immunodominant cytotoxic T epitope of the P protein at 
position 191-206. Two amino acid differences were found at positions 197 (alanine in RV-
97, valine in SAD B19) and 202 (threonine in RV-97, alanine in SAD B19). Alanine and 
valine are neutral, nonpolar, and hydrophobic and we assume that this difference does 
not have a major influence on the immunogenic properties of the strains. However, valine 
has a larger volume (105) and surface area (160), which may be important. The change 
from alanine to threonine at position 202 may be more important, because of the 
differences in the properties of these two amino acids, as was discussed for the N 
protein. 
 The structure of the antigenic site of the M protein at position 1-72 is different in 
the RV-97 and SAD B19 strains, and 11 amino acid changes were found during this 
study. The amino acid changes at positions 7, 22, and 44 of the M protein can be 
considered homologous, because the amino acids changed at the positions mentioned 
have similar chemical properties. Other changes may be relevant for differences in the 
antigenic properties of M protein. 
Nevertheless, only the N and G proteins are generally considered to be the most 
important for immunogenicity. The RV-97 strain has alanine and the SAD B19 strain 
possesses threonine located at position 407 of the nucleoprotein. Both of these amino 
acids are neutral but have major differences in volume, surface area, and polarity 
(alanine; volume 67, surface area 113, nonpolar; threonine: volume 93, surface area 146, 
polar). 
The antigenic properties of the glycoprotein were mostly compared between the 
RV-97 and SAD B19 strains, because both of them are used for the production of live 
attenuated oral vaccines. Fifty-four aa changes (almost 10% divergence) took place in 
the glycoprotein of the RV-97 strain when compared to the SAD B19 strain. Eight of 
these alterations are located within the major immunodominant epitope mapped at 
position 222-332 of the mature glycoprotein (Tordo, 1996). The first two changes at  
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positions 222 and 242, from alanine to serine and back, may be important, particularly for 
the specificity of antibodies than for the immunogenicity of the glycoprotein: both of these 
amino acids are neutral, but serine is a polar amino acid and alanine is non-polar, and 
consequently alanine is 5 times more soluble. However, these changes are reciprocal 
within twenty amino acids and the immunogenicity of this part of the sequence can be 
similar. The mutation of serine to proline at position 253 is considered important because 
they have similar properties, but proline may alter the rigidity of the aa chain. The 
mutation of proline to serine at position 253, and of lysine to glutamine at position 256 
may, be very important because proline is more hydrophobic than serine and lysine 
compared with glutamine, and is a very soluble amino acid. Moreover, the basic amino 
acid residues, such as lysine, are known to be essential for immunogenicity (Yi et al., 
2005). The mutations of arginine to histidine at position 264, arginine to lysine at position 
278, and of phenylalanine to isoleucine at position 318, seem to be conservative because 
these amino acids have similar properties. All of the vaccine strains analyzed during this 
study contain leucine at position 231, which represents the antigenic epitope 1 of the 
glycoprotein. The RV-97 and SAD B19 strains also contain identical structures at the 
antigenic site 2 (position 34-42 and 198-200), antigenic site 3 (position 330-338) and “a” 
(position 342-343). But the antigenic epitope VI at position 264 changes from histidine in 
RV-97 to arginine in SAD B19, both of these amino acids are basic but arginine has a 
greater volume and surface area. 
Because amino acid changes can potentially affect the folding of proteins which 
can have an influence on the conformational antigenic sites (epitopes) (Tordo, 1996; 
Moore et al., 2005), the differences determined can theoretically influence the 
immunological characteristics of the RV-97 strain. Further studies need to be conducted 
to support that because immunogenicity and pathogenicity of rabies virus have complex 
nature and is not fully understood yet. 
To differentiate between the field rabies viruses and vaccine strains, several 
techniques can be employed: sequencing of RT-PCR products, the cleavage of RT-PCR 
products with restriction enzymes, and real-time PCR. It was shown that the RT-PCR 
products of the G-L intergenic region of most of the vaccine strains are longer than those 
of the field viruses. The restriction enzyme technique and real-time PCR are now under 
development within the framework of the present project and the results of this study will 
soon be published. The preliminary studies have shown that these techniques to be fast, 
simple, and informative. 
  
58
The data included in this thesis can be used when planning the utilization of 
vaccines in different geographical regions. The wide genetic heterogeneity of field rabies 
virus strains was also verified in this study and indicates that we should remain alert to 
the potential spread of rabies and that international rabies-control programs must be 
established in rabies-affected areas. Data from this study has shown that it is necessary 
to continue investigating the genetic characteristics of the field and vaccine strains of 
rabies virus in order to determine their similarities and differences. 
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6. Concluding remarks 
Studies on rabies are considered to be very important by the international scientific 
community. Recently, several new genotypes were posited among Lyssaviruses, and 
further studies in this field are acknowledged. Genetic studies also help in the 
development of effective rabies-control programs, especially in wildlife. 
A diagnostic RT-PCR was developed during this study and is now in use as a 
supplementary method at Evira to support rabies diagnosis by FAT and cell-culture 
inoculation tests. With the help of a panel of mAbs, we found a great antigenic variability 
of the field rabies viruses in the Russian Federation. Further, genetic studies have helped 
to identify two major genetic groups. The Pan-Eurasian group comprises at least 4 
subgroups with viruses from different parts of Europe, Russia, and Kazakhstan. The 
Caucasian genetic group has not been previously defined. It comprises viruses from the 
Krasnodar region, an isolated region near the Georgian border, and also previously 
ungrouped viruses from Georgia and viruses from Iran. The distribution of the viruses 
from this group must be studied in the future, because other countries could be included 
in the area of circulation of the Caucasian strains. In the future, the Caucasian may be 
renamed the Trans-Caucasian group if viruses from other Caucasian countries are 
included. 
Currently, all the most widely used rabies vaccine strains have been sequenced 
and these sequences are available at the Gene Bank. In the present study we obtained 
the complete genome sequence of the vaccine strain RV-97 used in the Russian 
Federation for the production of the oral anti-rabies vaccine used to immunize wild 
carnivores. We also analyzed its antigenic and genetic properties in comparison with 
other rabies virus vaccine strains and compared the in vivo immunogenicity of the RV-97 
and SAD B19 in caged silver foxes. The differentiation between the field and vaccine 
strains of the rabies virus seem to be very important and several methods can be used to 
differentiate between these strains. In our study we used nucleotide sequencing for this 
purpose as it is very reliable, but laborious and very expensive. A more modern method, 
such as the restriction enzymes testing and real-time PCR would be a valuable asset for 
this purpose in the future. 
The data presented in this study can be used when planning rabies control 
programs in different geographical regions. The viral sequences obtained during this 
study are available to the public and can be used by other research groups in molecular-
epidemiological studies. 
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7. Заключение (concluding remarks in Russian) 
 
Научно-исследовательская работа в области диагностики, профилактики и 
борьбы с бешенством признана особо значимой международным сообществом. За 
последние годы было открыто несколько новых генотипов лиссавирусов и 
дальнейшие исследования в этой области имеют большое значение. Кроме того, 
результаты молекулярно-биологических исследований используются при 
разработке программ по борьбе с бешенством, особенно среди диких животных. 
В рамках данной работы был разработан метод диагностики бешенства 
основанный на обратно-транскриптазной полимеразной цепной реакции (ОТ-ПЦР). 
Данный метод используется в настоящее время в Финском Агентстве по 
Безопасности Продуктов Питания (Evira) в качестве дополнительного 
диагностического метода наряду с реакцией иммунофлюоресценции и выделением 
вируса бешенства в культуре клеток. Кроме того, он также использовался в нашей 
работе для получения ПЦР-продуктов с целью их последующего нуклеотидного 
секвенирования. 
С помощью панели моноклональных антител была изучена антигенная 
вариабельность изолятов вируса бешенства выделенных на территории 
Российской Федерации. Последующие генетические исследования позволили 
выявить две основные генетические группы. Пан-Евроазиатская группа включает 
как минимум 4 подгруппы, в которые входят вирусы из Казахстана и различных 
Европейских стран, включая Россию. Доступность референтных нуклеотидных 
последовательностей в международных базах данных позволила подтвердить 
достоверность наших исследований. Кавказская генетическая группа ранее не 
была обозначена как таковая. В неё входят вирусы выделенные в Краснодарском 
крае вблизи границы с Грузией, а также раннее выделенные вирусы в Грузии и 
Иране. В будущем эта группа может быть переименована в Транс-Кавказскую в 
случае если вирусы, принадлежащие к данной группе будут выявлены и в других 
странах кавказского региона. 
С появлением в международных базах данных большого числа полных 
последовательностей геномов вакцинных штаммов вируса бешенства, 
общепризнанной стала обязательность секвенирования полного генома всех 
используемых вакцинных штаммов. В результате проведенных нами исследований 
был получен полный геном вакцинного вируса бешенства, штамм РВ-97, 
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используемого в Российской Федерации для производства оральной 
антирабической вакцины. Был проведен сравнительный анализ генетических и 
антигенных свойства этого штамма в сравнении с другими вакцинными штаммами 
вируса бешенства. 
Дифференциация полевых изолятов и вакцинных штаммов вируса 
бешенства имеет большое значение. С этой целью используются несколько 
лабораторных методов. Кроме общепризнанного референтного метода – 
нуклеотидного секвенирования фрагментов генома, могут применяться и другие 
методы, такие как, обработка ПЦР-продуктов рестриктазами и ПЦР в реальном 
времени. 
  
62
8. Acknowledgments 
 The work for this thesis was conducted mainly at the Finnish Food Safety Authority 
(Evira). I would like to thank the Director General of Evira, Jaana Husu-Kallio, Professors 
Tuula Honkanen-Buzalski and Liisa Sihvonen who contributed a great deal to Finnish-
Russian collaboration on rabies control within the framework of which most of the results 
of the present study were obtained. I would also like to thank all the staff of the Virology 
Unit for their help in my work with special thanks to Docent Anita Huovilainen and 
Professor Erkki Neuvonen, without whom this work could not have been done. Special 
thanks go to DVM Cristine Ek-Kommonen for her help in case report preparation and Arja 
Engblom and Tiina Peltonen for their excellent technical assistance. 
 I want to express my gratitude to the Dean of the Faculty of Veterinary Medicine at 
the University of Helsinki Professor Antti Sukura for his supervision of my PhD work and 
to Professor Olli Vapalahti (Haartman Institute) for his help in preparing the manuscripts 
of several articles and this thesis. I also would like to thank Helsinki University for 
granting me in this project. 
 I also would like to thank our collaborators from the Institute of Biotechnology 
(University of Helsinki) head of the DNA sequencing laboratory Lars Paulin and Sini 
Suomalainen for their help in obtaining the entire genome sequence of the vaccine strain. 
 The help of Dr. Evgeniy Belik, Professor Sergey Rybakov, Professor Valery 
Mikhalishin, Professor Konstantine Gruzdev and Dr. Alexey Borisov is very much 
appreciated. I thank them and all the staff at the FGI “Federal Centre for Animal Health” 
for their help in all aspects of my work. The supervisor of the Finnish-Russian 
collaboration on rabies control performed by Dr. Sergey Yakovlev from the Federal 
Veterinary and Phytosanitary Service of the Russian Federation is also greatly 
appreciated. 
Conducting research abroad and writing this thesis often took me away from my 
family for long periods of time and I want to thank my wife Mariya Metlina for her patience 
with me. 
 This thesis was supported by the University of Helsinki, the Finnish Food Safety 
Authority and the Finnish Ministry of Agriculture and Forestry. 
  
63
9. References 
1. Adeiga, A.A., Audu, R.A., 1996. Detection of rabies virus in saliva of 
apparently healthy dogs. Biomed. Lett. 54, 207-212. 
2. Albertini, A.A.V., Wernimont, A.K., Muziol, T., Ravelli, R.B.G., Clapier, C.R., 
Schoehn, G., Weissenhorn, W., Ruigrok, R.W.H., 2006. Crystal structure of 
the rabies virus nucleoprotein-RNA complex. Science. 313, 360-363. 
3. Arai, Y.T., Kuzmin, I.V., Kameoka, Y., Botvinkin, A.D., 1997. Nucleoprotein 
gene analysis of fixed and street rabies virus variants using RT-PCR. Arch. 
Virol. 142, 1787-1796. 
4. Arai, Y.T., Kuzmin, I.V., Kameoka, Y., Botvinkin, A.D., 2003. New 
Lyssavirus genotype from the lesser mouse-eared bat (Myotis blythi), 
Kyrghyzstan. Emerg. Infect. Dis. 9, 333-337. 
5. Arguin, P.M., Murray-Lillibridge, K., Miranda, M.E., Smith, J.S., Calaor, A.B., 
Rupprecht, C.E., 2002. Serologic evidence of Lyssavirus infections among 
bats, the Philippines. Emerg. Infect. Dis. 8, 258-262. 
6. Artois, M., 1992. Transmission of rabies and impact on a population of 
foxes (mammalian, Vulpes vulpes L.). Mesogil. 52, 82. 
7. Atanasiu, P., 1973. Quantitative assay and potency test of antirabies serum 
and immunoglobulin. In: Kaplan, M.M., Koprowski, H., (Eds). Laboratory 
techniques in rabies. vol. 2, 3rd ed. Geneva: World Health 
Organization/WHO Monograph Series. pp. 314–318. 
8. Aubert, M., 1994. Control of rabies in foxes: what are the appropriate 
measures? Vet Rec. 134, 55-59. 
9. Aubert, M.F., Masson, E., Artois, M., Barrat, J., 1994. Oral wildlife rabies 
vaccination field trials in Europe, with recent emphasis on France. Curr. 
Top. Microbiol. Immunol. 187, 219-243. 
10. Baer, G.M., Abelseth, M.K., Debbie, J.G., 1975. Oral vaccination of foxes 
against rabies. Am. J. Epidemiol. 93, 487-490. 
11. Baer, G.M., 1991. The natural History of Rabies. Academic Press, pp. 268-
269. 
12. Bacon, P.J., Macdonald, D.W., 1980. To control rabies: vaccinate foxes. 
New Scientist. 87, 640-645. 
13. Badrane, H., Bahloul, C., Perrin, P., Tordo, N., 2001. Evidence of two 
Lyssavirus phylogroups with distinct pathogenicity and immunogenicity. J. 
Virol. 75, 3268-3276. 
14. Badrane, H., Tordo, N., 2001. Host Switching in Lyssavirus History from the 
Chiroptera to the Carnivora Orders. J. Virol. 75, 8096–8104. 
15. Bahloul, C., Jacob, Y., Tordo, N., Perrin, P., 1998. DNA-based 
immunization for exploring the enlargement of immunological cross-
reactivity against the lyssaviruses. Vaccine. 16, 417-425. 
16. Bahloul, C., Ahmed, S.B., B'chir, B.I., Kharmachi, H., Hayouni, A., Dellagi, 
K., 2003. Post-exposure therapy in mice against experimental rabies: a 
single injection of DNA vaccine is as effective as five injections of cell 
culture-derived vaccine. Vaccine. 22, 177-184. 
17. Ballard, W.B., Follmann, E.H., Ritter, D., Robards, M.D., Cronin, M.A., 
2001. Rabies and canine distemper in an arctic fox population in Alaska. J. 
Wildlife Dis. 37, 133-137. 
18. Barnard, B.J.H., Voges, S.F., 1982. A simple technique for the rapid 
diagnosis of rabies in formalin-preserved brain. Onderstepoort J. Vet. Res. 
49, 1993-1994. 
  
64
 
19. Beauregard, M., Boulanger, P., Webster, W.A., 1965. The use of 
fluorescent antibody staining in the diagnosis of rabies. Can. J. Comp. Med. 
and Vet. Science. 29, 141-147. 
20. Benmansour, A., Leblois, H., Coulon, P., Tuffereau, C., Gaudin, Y., 
Flamand, A., Lafay, F., 1991. Antigenicity of rabies virus glycoprotein. J. 
Virol. 65, 4198-4203. 
21. Benjavongkulchai, M., Kositprapa, C., Limsuwun, K., Khawplod, P., 
Thipkong, P., Chomchey, P., Yountong, C., Naraporn, N., Ayuthya, A.B., 
Raksakate, S., Samranwetaya, P., Oka, T., Ohkuma, K., Hamasaki, T., 
Wilde, H., 1997. An immunogenicity and efficacy study of purified chick 
embryo cell culture rabies vaccine manufactured in Japan. Vaccine. 15, 
1816-1819. 
22. Bernardi, F., Nadin-Davis, S.A., Wandeler, A.I., Armstrong, J., Gomes, A.A., 
Lima, F.S., Nogueira, F.R., Ito, F.H., 2005. Antigenic and genetic 
characterization of rabies viruses isolated from domestic and wild animals 
of Brazil identifies the hoary fox as a rabies reservoir. J. Gen. Virol. 86, 
3153-3162. 
23. Bingham, J., Schumacher, C.L., Aubert, M.F.A. Hill, F.W.G., Aubert, A., 
1997. Innocuty studies of SAG-2 oral rabies vaccine in various Zimbabwean 
wild non-target species. Vaccine. 15, 937-943. 
24. Bingham, J., Schumacher, C.L., Hill, F.W.G., Aubert, A., 1999. Efficacy of 
SAG2 oral rabies vaccine in two species of jackal (Canis adustus and Canis 
mesomelas). Vaccine. 17, 551-558. 
25. Bingham, J., 2005. Canine rabies ecology in southern Africa. Emerg. Infect. 
Dis. 11, 1337-1342. 
26. Blancou, J., 1994. Early methods for the surveillance and control of rabies 
in animals. Rev. Sci. Tech. Off. Int. Epiz. 13, 361-372. 
27. Blancou, J., 2004. Rabies in Europe and the Mediterranean Basin: from 
antiquity to the 19th century. In: King, A.A., Fooks, A.R., Aubert, M., 
Wandeler, A.I., (Eds.) Historical perspectives of Rabies in Europe and the 
Mediterranean Basin, OIE, pp. 15-24. 
28. Black, E.M., McElhinney, L.M., Lowings, J.P., Smith, J., Johnstone, P., 
Heaton, P.R., 2000. Molecular methods to distinguish between classical 
rabies and the rabies-related European bat lyssaviruses. J. Virol. Meth. 87, 
123-131. 
29. Black, E.M., Lowings, J.P., Smith, J., Heaton, P.R., McElhinney, L.M., 2002. 
A rapid RT-PCR method to differentiate six established genotypes of rabies 
and rabies-related viruses using TaqMan technology. J. Virol. Meth. 105, 
25-35. 
30. Bordignon, J., Comin, F., Ferreira, S., Caporale, G., Lima Filho, J., Zanetti, 
C., 2002. Calculating rabies virus neutralizing antibodies titers by flow 
cytometry. Rev. Inst. Med. Trop. 44, 151-154. 
31. Borisov, A.V., Toloknov, A.C., Metlin, A.E., Mikhalishin, V.V., Rybakov, 
S.S., 2002. Efficacy and safety testing of the viral vaccine “Sinrab” on the 
targeted species. Scientific notes of Vitebsk State Academy of Veterinary 
Medicine. Vitebsk, Belarus, 38, 15-18. 
32. Botvinkin, A.D., Savitskiĭ, V.P., Sidorov, G.N., Iudin, V.G., 1981. Importance 
of the raccoon dog in the epidemiology and epizootiology of rabies in the 
Far East. Zh. Mikrobiol. Epidemiol. Immunobiol. 12, 79-82. 
  
65
 
33. Botvinkin, A.D., Selimov, M.A., Kliueva, E.V., Gribanova, L., Khismatullina, 
N.A., 1990. The antigenic characteristics of field strains of the rabies virus 
from different districts of the USSR studied using antinucleocapsid 
monoclonal antibodies. Zh, Mikrobiol, Epidemiol, Immunobiol. 1, 50-54. 
34. Botvinkin, A.D., Poleschuk, E.M., Kuzmin, I.V., Borisova, T.I., Gazaryan, 
S.V., Yanger, P., Rupprecht, C.E., 2003. Novel Lyssaviruses isolated from 
bats in Russia. Emerg. Inf. Dis. 9. 1623-1625. 
35. Botvinkin, A.D., Kuzmin, I.V., McElhinney, L.M., Johnson, N., Fooks, A.R., 
2006. The diversity of rabies virus in Russia demonstrated by anti-
nucleocapsid monoclonal antibody application and limited gene sequencing. 
Dev. Biol. 125, 79-90. 
36. Bourgon, A.R., Charlton, K.M., 1987. The demonstration of rabies antigen in 
paraffin-embedded tissues using the peroxidase-antiperoxidase method: a 
comparative study. Can. J. Vet Res. 51, 117-120. 
37. Bourhy, H., Tordo, N., Lafon, M., Sureau, P., 1989. Complete cloning and 
molecular organization of a rabies-related virus, Mokola virus. J. Gen. Virol. 
70, 2063-2074. 
38. Bourhy, H., Kissi, B., Audry, L., Smreczak, M., Sadkowska-Todys, M., 
Kulonen, K., Tordo, N., Zmudzinski, J.F., Holmes, E.C., 1999. Ecology and 
evolution of rabies virus in Europe. J. Gen. Virol. 80, 2545-2557. 
39. Brass, D.A., 1994. Rabies in bats — natural history and public health 
implications. Livia Press, Ridgefield, 352. 
40. Briggs, D.J., Dreesen, D.W., Morgan, P., Chin, J.E., Seedle, C.D., Cryz, L., 
Gluck, R., Cryz, S.J., 1996. Safety and immunogenicity of Lyssavac Berna 
human diploid cell rabies vaccine in healthy adults. Vaccine. 14, 1361-1365. 
41. Brochier, B.M., Languet, B., Blancou, J., Kieny, M.P., Lecocq, J.P., Costy, 
F., Desmettre, P., Pastoret, P.P., 1988. Use of recombinant vaccinia-rabies 
virus for oral vaccination of fox cubs (Vulpes vulpes, L) against rabies. Vet. 
Microbiol. 18, 103-108. 
42. Brochier, B., Blancou, J., Thomas, I., Languet, B., Artois, M., Kieny, M.P., 
Lecocq, J.P., Costy, F., Desmettre, P., Chappuis, G., Pastoret P., 1989. 
Use of recombinant vaccinia-rabies glycoprotein virus for oral vaccination of 
wildlife against rabies: innocuity to several non-target bait consuming 
species. J. Wildl. Dis. 25, 540-547. 
43. Brochier, B., Thomas, I., Bauduin, B., Leveau, T., Pastoret, P.P., Languet, 
B., Chappuis, G., Desmettre, P., Blancou, J., Artois, M., 1990. Use of a 
vaccinia-rabies recombinant virus for the oral vaccination of foxes against 
rabies. Vaccine. 8, 101-104. 
44. Brochier, B., Kieny, M.P., Costy, F., Coppens, P., Bauduin, B., Lecocq, J.P., 
Languet, B., Chappuis, G., Desmettre, P., Afiademanyo, K., Libois R., 
Pastoret P., 1991. Large-scale eradication of rabies using recombinant 
vaccinia-rabies vaccine. Nature. 354, 520-522. 
45. Brochier, B., Aubert, M.F.A., Pastoret, P.P., Masson, E., Schon, J., 
Lombard, M., Chappuis, G., Languet, B., Desmettre, P., 1996. Field use of 
a vaccina-rabies recombinant vaccine for the control of sylvatic rabies in 
Europe and North America. Rev. Sci. Tech. Off. Int. Epiz. 15, 947-970. 
  
66
 
46. Brozka, K., Finke, S., Conzelmann, K.K., 2005. Identification of rabies virus 
alpha/beta interferon antagonist: phosphoprotein P interferes with 
phosphorylation of interferon regulatory factor 3. J. Virol. 79, 7673-7681. 
47. Bryceson, A.D., Greenwood, B.M., Warrell, D.A., Davidson, N.M., Pope, 
H.M., Lawrie, J.H., Barnes, H.J., Bailie, W.E., Wilcox, G.E., 1975. 
Demonstration during life of rabies antigen in humans. J. Infect. Dis. 131, 
71-74. 
48. Bunschoten, H., Gore, M., Claassen, I.J., Uytdehaag, F.G., Dietzschold, B., 
Wunner, W.H., Osterhaus, A.D., 1989. Characterization of a new virus-
neutralizing epitope that denotes a sequential determinant on the rabies 
virus glycoprotein. J. Gen. Virol. 70, 291-298. 
49. Celer, V., Belay, G., Celer, V., 1991. Kinetics of rabies virus replication in 
cell cultures. Acta. Vet. BRNO. 60, 161-164. 
50. Chare, E.R., Gould, E.A., Holmes, E.C., 2003. Phylogenetic analysis 
reveals a low rate of homologous recombination in negative-sense RNA 
viruses. J. Gen. Virol. 84, 2691-2703. 
51. Charey, A.B., McLean, R.G., 1983. The ecology of rabies: evidence of co-
adaptation. J. Appl. Ecol. 20, 777-800. 
52. Charlton K.M., 1994. The pathogenesis of rabies and other lyssaviral 
infections: recent studies. In: Rupprecht, C.E., Dietzschold, B., Koprowski, 
H. (Eds.) Lyssaviruses. Springer-Verlang, Berlin Heidelberg New York, pp. 
95-115. 
53. Chenik, M., Chebli, K., Gaudin, Y., Blondel, D., 1994. In vivo interaction of 
rabies virus phosphoprotein (P) and nucleoprotein (N): existence of two N-
binding sites on P protein. J. Gen. Virol. 75, 2889-2896. 
54. Chenik, M., Chebli, K., Blondel, D., 1995. Translation initiation at alternate 
in-frame AUG codons in the rabies virus phosphoprotein mRNA is mediated 
by a ribosomal leaky scanning mechanism. J. Virol. 69, 707-712. 
55. Chenik, M., Schnell, M., Conzelmann, K.K., Blondel, D., 1998. Mapping the 
interacting domains between the rabies virus polymerase and 
phosphoprotein. J. Virol. 72. 1925-1930. 
56. Childs, J.E., Colby, L, Krebs, J.W., Strine, T., Feller, M., Noah, D., Drenzek, 
C., Smith J.S., Rupprecht, C.E., 1997. Surveillance and spatiotemporal 
associations of rabies in rodents and lagomorphs in the United States, 
1985-1994. J. Wildl. Dis. J33, 20-27. 
57. Childs, J.E., Curns, A.T., Dey, M.E., Real, L.A., Feinstein, L., Bjornstad, 
O.N., Krebs, J.W., 2000. Predicting the local dynamics of epizootic rabies 
among raccoons in the United States. Proc Natl Acad Sci USA. 97, 13666-
13671. 
58. Clark, H.F., 1980. Rabies serogroup viruses in neuroblastoma cells: 
propagation, "Autointerference", and apparently random back-mutation of 
attenuated viruses to the virulent state. Infect. Immun. 27, 1012-1022. 
59. Cliquet, F., Aubert, M., Sagne, L., 1998. Development of a fluorescent 
antibody virus neutralisation test (FAVN test) for the quantitation of rabies-
neutralising antibody. J. Immunol. Meth. 212, 79-87. 
60. Cliquet, F., Sagne, L., Schereffer, J.L., Aubert, M.F., 2000. ELISA test for 
rabies antibody titration in orally vaccinated foxes sampled in the fields. 
Vaccine. 18, 3272-3279. 
  
67
 
61. Cliquet, F., Muller, T., Mutinelli, F., Geronutti, S., Brochier, B., Selhorst, T., 
Schereffer, J.L., Krafft, N., Burow, J., Schameitat, A., Schluter, H., Aubert, 
M., 2003. Standartisation and establishment of a rabies ELISA test in 
European laboratories for assessing the efficacy of oral fox vaccination 
campaigns. Vaccine. 21, 2986-2993. 
62. Cliquet, F., McElhinney, L.M., Servat, A., Boucher, J.M., Lowings, J.P., 
Goddard, T., Mansfield, K.L., Fooks, A.R., 2004. Development of a 
qualitative indirect ELISA for the measurement of rabies virus-specific 
antibodies from vaccinated dogs and cats. J. Virol. Meth. 117, 1-8. 
63. Cliquet, F., Gurbuxani, J.P., Pradhan, H.K., Pattnaik, B., Patil, S.S., 
Regnault, A., Begouen, H., Guiot, A.L., Sood, R., Mahl, P., Singh, R., 
Meslin, F.X., Picard, E., Aubert, M.F., Barrat, J., 2007. The safety and 
efficacy of the oral rabies vaccine SAG2 in Indian stray dogs. Vaccine. 25, 
3409-3418. 
64. Conzelmann, K., Cox, J., Schneider, L., Thiel, H., 1990. Molecular cloning 
and complete nucleotide sequence of the attenuated rabies virus SAD B19. 
Virology. 175, 485-499. 
65. Cox, J.H., Schneider, L.G., Muller, W.W., 1992. Eine antigenvariante der 
fuchstollwut in Europa. Tierarztl. Umschau. 47, 824-828. 
66. Crepin, P., Audry, L., Rotivel, Y., Gacoin, A., Caroff, C., Bourhy, H., 1998. 
Intravitam diagnosis of human rabies by PCR using saliva and 
cerebrospinal fluid. J. Clin. Microbiol. 36, 1117-1121. 
67. David, D., Yakobson, B., Smith, J.S., Stram, Y., 2000. Molecular 
epidemiology of rabies virus isolates from Israel and other middle- and 
Near-Eastern countries. J. Clin. Microbiol. 38, 755-762. 
68. Davis, P.L., Bourhy, H., Holmes, E.C., 2006. The evolutionary history 
and dynamics of bat rabies virus. Infection, Genetics and Evolution. 6, 464–
473. 
69. Dean, D.J., Abelseth, M.K., Atanasiu, P., 1996. The fluorescent antibody 
test. In: Meslin, F.-X., Kaplan, M.M., Koprowski H., (Eds.). Laboratory 
Techniques in Rabies. Geneva, pp. 88-93. 
70. Delpietro, H.A., Gury-Dhomen, F., Larghi, O.P., Mena-Segura, C., Abramo, 
L., 1997. Monoclonal antibody characterization of rabies virus strains 
isolated in the River Plate Basin. Zentralbl. Veterinarmed B. 44, 477-483. 
71. Delpietro, H.A., Larghi, O.P., Russo, R.G., 2001. Virus isolation from saliva 
and salivary glands of cattle naturally infected with paralytic rabies. 
Preventive Vet. Med. 48, 223-228. 
72. De Mattos, C.A., De Mattos, C.C., Smith, J.S., Miller, E.T., Papo, S., Utrera, 
A., Osburn, B.I., 1996. Genetic characterization of rabies field isolates from 
Venezuela. J. Clin. Microbiol. 34, 1553-1558. 
73. De Mattos, C.C., De Mattos, C.A., Loza-Rubio, E., Aguilar-Setien, A., 
Orciari, L.A., Smith, J.S., 1999. Molecular characterization of rabies virus 
isolates from Mexico: implications for transmission dynamics and human 
risk. Am. J. Trop. Med. Hyg. 6, 587-597. 
74. Desmettre, P., Languet, B., Chappuis, G., Brochier, B., Thomas, I., Lecocq, 
J.P., Kieny, M.P., Blancou, J., Aubert, M., Artois, M., Pastoret, P.P., 1990. 
Use of vaccinia rabies recombinant for oral vaccination of wildlife. Vet. 
Microbiol. 23, 227-236. 
  
68
75. Dietzschold, B., Lafon, M., Wang, H., Otvos, L., Celis, E., Wunner, W.H., 
Koprowski, H., 1987. Localization and immunological characterization oh 
antigenic domains of rabies virus internal N and NS proteins. Virus res. 8, 
103-125. 
76. Dietzschold, B., Faber, M., Schnell, M., 2003. New approaches to the 
prevention and eradication of rabies. Expert Rev. Vaccines. 2, 89-96. 
77. Dietzschold, B., Schnell, M., Koprowski H., 2005. Pathogenesis of rabies. 
Curr. Top. Microbiol. Immunol. 292, 45-56. 
78. Dressen, D.W., 1997. A global review of rabies vaccines for human use. 
Vaccine. 15, 2-6. 
79. Dudnikov, S.A., 2003a. Epizootic rabies situation in Russia (1991-2002): I. 
Diagnostic aspects. Proceedings of the conference in commemoration of 
the 45th anniversary of the ARRIAH, 103-108. 
80. Dudnikov, S.A., 2003b. Epizootic rabies situation in Russia (1991-2002): II. 
Epizootologic aspects. Proceedings of the conference in commemoration of 
the 45th anniversary of the ARRIAH, 108-112. 
81. Ertl, H.C., Dietzschold, B., Gore, M., Otvos, L.J., Larson, J.K., Wunner, 
W.H., Koprowski, H., 1989. Induction of rabies virus-specific T-helper cells 
by synthetic peptides that carry dominant T-helper cell epitopes of the viral 
ribonucleoprotein. J Virol. 63, 2885-92. 
82. Esterhuysen, J., Prehaud, C., Thomos, G.R., 1995. A liquid-phase blocking 
ELISA for detection of antibodies to rabies virus. J. Virol. Meth. 51, 31-42. 
83. Faber, M., Pulmanausahakul, R., Hodawadekar, S.S., Spitsin, S., 
McGettigan, J.P., Schnell, M.J., Dietzschold, B., 2002. Overexpression of 
the rabies virus glycoprotein results in enhancement of apoptosis and 
antiviral immune response. J Virol. 76, 3374-3381. 
84. Favoretto, S.R., Carrier, M.L., Cunha, E.M.S., Aguiar, E.A., Silva, L.H., 
Sodre, M.M., Souza, M.C., Kotait, I., 2002. Antigenic typing of Brazilian 
rabies virus samples isolated from animals and humans, 1989-2000. Rev. 
Inst. Med. Trop. 44, 91-95. 
85. Fekadu, M., Chandler, F.W., Harrison, A.K., 1982. Pathogenesis of rabies in 
dogs inoculated with Ethiopian rabies virus strain. Immunofluorescence, 
histological and ultrastructural studies of central nervous system. Arch. 
Virol. 71, 109-126. 
86. Fekadu, M., Nesby, S.L., Shaddock, J.H., Schumacher, C.L., Linhart, S.B., 
Sanderlin, D.W., 1996. Immunogenicity, efficacy and safety of an oral rabies 
vaccine (SAG2) in dogs. Vaccine. 14, 465-468. 
87. Flamand, A., Coulon, P., Lafay, F., Tuffereau, C., 1993. Avirulent mutants of 
rabies virus and their use as a live vaccine. Trends Microbiol. 1, 317. 
88. Fodor, I., Grabko, V.I., Khozinski, V.V., Selimov, M.A., 1994. Nucleotide and 
deduced amino acid sequences of glycoprotein gene of rabies virus vaccine 
strain Vnukovo-32. Arch. Virol. 135, 451-459. 
89. Fooks, A.R., McElhinney, L.M., Pounder, D.J., Finnegan, C.J., Mansfield, 
K., Johnson, N., Brookes, S.M., Parsons, G., White, K., McIntyre, P.G., 
Nathwani, D., 2003. Case report: isolation of a European bat lyssavirus type 
2a from a fatal human case of rabies encephalitis. J. Med. Virol. 71, 281-
289. 
90. Follmann, E.H., Ritter, D.G., Baer, G.M., 1996. Evaluation of the safety of 
two attenuated oral rabies vaccines, SAG1 and SAG2, in six Arctic 
mammals. Vaccine. 14, 270-273. 
  
69
91. Fraser, G.C., Hooper, P.T., Lunt, R.A., Gould, A.R., Gleeson, L.J., Hyatt, 
A.D., Russel, G.M., Kattenbelt, J.A., 1996. Encephalitis caused by a 
lyssavirus in fruit bats in Australia. Emerg. Infect. Dis. 2, 327-331. 
92. Gaudin, Y., Ruigrok, R.W., Tuffereau, C., Knossow, M., Flamand, A., 1992. 
Rabies virus glycoprotein is a trimer. Virology. 187, 627-632. 
93. Gode, G.R., Bhide, N.K., 1988. Two rabies deaths after corneal grafts from 
one donor. Lancet, October 1, p. 791. 
94. Gould, A.R., Hyatt, A.D., Lunt, R., Kattenbelt, J.A., Hengstberger, S., 
Blacksell, S.D., 1998. Characterization of a novel lyssavirus isolated from 
Pteropid bats in Australia. Virus. Res. 54, 165-187. 
95. Goldwasser, R.A., Kissling, R.E., 1958. Fluorescent antibody staining of 
street and fixed rabies virus antigens. Proc. Soc. Exper. Biol. Med. 98, 219-
223. 
96. Goldwasser, R.A., Kissling, R.E., Carski, T.R., 1959. Fluorescent antibody 
staining of rabies virus antigens in the salivary glands of rabid animals. Bull. 
WHO. 20, 579-588. 
97. Goto, H., Minamoto, N., Ito, H., Ito, N., Sugiyama, M., Kinjo, T., Kawai, A., 
2000. Mapping of epitopes and structural analysis of antigenic sites in the 
nucleoprotein of rabies virus. J. Gen. Virol. 81, 119-127. 
98. Gram, G., 1996. Rabies situation and oral vaccination of foxes in Austria. 
WHO Conference on Oral Immunization of Foxes Against Rabies in Central 
and Eastern Europe. Slovenia, Portroz, 33-43. 
99. Grenfell, B.T., Pybus, O.G., Gog, J.R., Wood, J.L., Daly, J.M., Mumford, 
J.A., Holmes, E.C., 2004. Unifying the epidemiological and evolutionary 
dynamics of pathogens. Science. 303, 327-332. 
100. Gribencha, S.V., Gribanova, L.Y., Malkov, G.B., Barinsky, I.F., 1989. 
Population structure of some street rabies virus strains. Arch. Virol. 104, 
347-350. 
101. Gribencha, S.V., Vasilenko, O.V., Kuz'mitskaia, T.M., Furalev, V.A., 
Sveshnikov, P.G., Tatarov, A.G., Kolotvina, P.V., Barinskiĭ, I.F., 1991a. The 
interaction of monoclonal antibodies to the structural proteins of the 
Vnukovo-32 vaccinal virus with other viruses of the rabies group. Vopr. 
Virusol. 36, 399-402. 
102. Gribencha, S.V., Vasilenko, O.V., Furalev, V.A., Kliushnik, S., Kuz'mitskaia, 
T.M., Sveshinkov, P.G., Barinskiĭ, I.F. 1991b. The isolation and 
characteristics of hybridomas producing monoclonal antibodies to the 
structural proteins of the Vnukovo-32 strain of the rabies virus. Vopr. 
Virusol. 36, 318-321 
103. Gruzdev, K.N., Nedosekov, V.V., 2001. Rabies of Animals. Moscow, 
Akvarium, p. 57. 
104. Guyatt, K.J., Twin, J., Davis, P., Holmes, E.C., Smith, G.A., Smith, I.L., 
Mackenzie, J.S., Young, P.L., 2003. A molecular epidemiological study of 
Australian bat lyssavirus. J. Gen. Virol. 84, 485-496. 
105. Gylys, L., Chomel, B.B., Gradner, I.A., 1998. Epidemiological surveillance of 
rabies in Lithuania from 1986-1996. Rev. Sci. Tech. Off. Int. Epiz. 17, 691-
698. 
106. Heaton, P.R., McElhinney, L.M., Lowings, J.P., 1999. Detection and 
identification of rabies and rabies related viruses using rapid-cycle PCR. J. 
Virol. Meth. 81, 63-69. 
  
70
107. Hellenbrand, W., Meyer, C., Rasch, G., Steffens, I., Ammon, A., 2005. 
Cases of rabies in Germany following organ transplantation. Euro. Surveill. 
10, E050224.6 
108. Hiramatsu, K., Mifune, K., Mannen, K., Nishizono, A., Kawano, H., Ito, Y., 
Kawai, A., 1992. Mapping of the antigenic determinants recognized by 
monoclonal antibodies against the M2 protein of rabies virus. Virology. 187, 
472-479. 
109. Holmes, E.C., Woelk, C.H., Kassis, R., Bourhy, H., 2002. Genetic 
constraints and the adaptive evolution of rabies virus in nature. Virology. 
292, 247-257. 
110. Hostnik, P., 2000a. The modification of fluorescent antibody virus 
neutralization (FAVN) test for detection of antibodies to rabies virus. J. Vet. 
Med. 47, 423-427. 
111. Hostnik, P., 2000b. Rabies in Slovenia and its control. WHO meeting of 
rabies control for veterinary experts in middle and east European countries. 
Estonia, Tallinn, 15-20. 
112. Hu, L., Ngichabe, C., Trimarchi, C.V., Esposito, J.J., Scott, F.W., 1997. 
Raccoon poxvirus live recombinant feline panleukopenia virus VP2 and 
rabies virus glycoprotein bivalent vaccine. Vaccine. 15, 1466-1472. 
113. Hyun, B.H., Lee, K.K., Kim, I.J., Lee, K.W., Park, H.J., Lee, O.S., An, S.H., 
Lee, J.B., 2005. Molecular epidemiology of rabies virus isolates from South 
Korea. Virus Res. 114, 113-125. 
114. Ito, M., Itou, T., Sakai, T., Santos, M.F., Arai, Y.T., Takasaki, T., Kurane, I., 
Ito, F.H., 2001a. Detection of rabies virus RNA isolated from several 
species of animals in Brazil by RT-PCR. J. Vet. Med. Sci. 63, 1309-1313. 
115. Ito, N., Kakemizu, M., Ito, K., Yamamoto, A., Yoshida, Y., Sugiyama M., 
Minamoto N., 2001b. A comparison of complete sequences of the 
attenuated RC-HL strain of rabies virus used for production of animal 
vaccine in Japan, and the parental Nishigahara strain. Microbiol. Immunol. 
45, 51-58. 
116. Ito, M., Itou, T., Shoji, Y., Sakai, T., Ito, F.H., Arai, Y.T., Takasaki, T., 
Kurane, I. 2003. Discrimination between dog-related and vampire bat-
related rabies viruses in Brazil by strain-specific reverse transcriptase-
polymerase chain reaction and restriction fragment length polymorphism 
analysis. J. Clin. Virol. 26, 317-330. 
117. Jacob, Y., Real, E., Tordo, N., 2001. Functional interaction map of 
lyssavirus phosphoprotein: identification of the minimal transcription 
domains. J. Virol. 75, 9613-9622. 
118. Jackson, A.C., 1991. Biological basis of rabies virus neurovirulence in mice: 
comparative pathogenesis study using the immunoperoxidase technique. J. 
Virol. 65, 537-540. 
119. Johnson, N., McElhinney, M., Smith, J., Lowings, P., Fooks, A.R., 2002a. 
Phylogenetic comparison of the genus Lyssavirus using distal coding 
sequences of glycoprotein and nucleoprotein genes. Arch. Virol. 147, 2111-
2123. 
120. Johnson, N., Mansfield, K.L., Fooks, A.R., 2002b. Canine vaccine recipients 
recognize an immunodominant region of the rabies virus glycoprotein. J. 
Gen. Virol. 83, 2663-2669. 
121. Johnson, N., Fooks, A.R., 2005. Archival study of a Finnish isolate from the 
1988/89 rabies outbreak. Arch. Virol. 150, 1407-1414. 
  
71
122. Johnson, N., Un, H., Vos, A., Aylan, O., Fooks, A.R. 2006. Wildlife rabies in 
Western Turkey: the spread of rabies through the western provinces of 
Turkey. Epidemiol. Infect. 134, 369-375. 
123. Johnson, P.K., Swoveland, P.T., Emmons, R.W., 1980. Diagnosis of rabies 
by immunofluorescence in trypsin-treated histologic sections. J. Am. Med. 
Assoc. 4, 41-43. 
124. Kaplan, M.M., 1996. Safety precautions in handling rabies virus. In: Meslin, 
F.-X., Kaplan, M.M., Koprowski, H., (Eds.). Laboratory techniques in rabies. 
4th edition, WHO, Geneva, pp. 3-7. 
125. Kasempimolporn, S., Saengseesom, W., Lumlertdacha, B., Sitprija, V., 
2000. Detection of rabies virus antigen in dog saliva using a latex 
agglutination test. J. Clin. Microbiol. 38, 3098-3099. 
126. Kasempimolporn, S., Saengseesom, W., Tirawatnapong, T., 
Puempumpanich, S., Sitprija, V., 2004. Genetic typing of feline rabies virus 
isolated in greater Bangkok, Thailand. Microbiol Immunol. 48, 307-311. 
127. Kasempimolporn, S., Sichanasai, B., Saengseesom, W., Puempumpanich, 
S., Chatraporn, S., Sitprija, V., 2007. Prevalence of rabies virus infection 
and rabies antibody in stray dogs: A survey in Bangkok, Thailand. Prev. 
Vet. Med. 78, 325-332. 
128. Katayama, S., Yamanaka, M., Ota, S., Shimizu, Y., 1999. A new 
quantitative method for rabies virus by detection of nucleoprotein in virion 
using ELISA. J. Vet. Med. Sci. 61, 411-416. 
129. Kendall, D.G., 1957. Discussion of `Measles periodicity and community size' 
by M. S. Bartlett. J. Roy. Stat. Soc. 120, 48-70. 
130. Kihm, U., Flamand, A., Pastoret, P.P., Peterhans, E., 1992. Round table on 
epidemiology and control of fox rabies. Vet. Microbiol. 33, 297-301. 
131. Kilic, B., Unal, B., Semin, S., Konakci, S.K., 2006. An important public 
health problem: rabies suspected bites and post-exposure prophylaxis in a 
health district in Turkey. Int. J. Infect. Dis. 10, 248-254. 
132. King, A.A., Fooks, A.R., Aubert, M., Wandeler, A.I., 2004. Historical 
perspectives of Rabies in Europe and the Mediterranean Basin, OIE. 
133. Kissi, B., Tordo, N., Bourhy, H., 1995. Genetic polymorphism in the rabies 
virus nucleoprotein gene. Virology. 209, 526–537. 
134. Kissling, R.E., 1975. The fluorescent antibody test in rabies. In: Baer G.M. 
The natural history of rabies. Academic Press, Vol. 1, pp. 401-416. 
135. Koprowski, P., 1996. The mouse inoculation test. Laboratory Techniques in 
Rabies. Meslin, F.-X., Kaplan, M.M., Koprowski, H. Geneva, pp. 85-93. 
136. Koprowski H., 2002. Old and new prescriptions for infectious diseases and 
the newest recipes for biomedical products in plants. Arch. Immunol. Ther. 
Exp. 50, 365-369. 
137. Krebs, J.W., Wilson, M.L., Childs, J.E., 1995. Rabies - epidemiology, 
prevention, and future research. J. Mammalogy. 76, 681-694. 
138. Krebs, J.W., Wheeling, J.T., Childs, J.E., 2003. Rabies surveillance in the 
United States during 2002. J. Amer. Vet. Med. Assoc. 223, 1736-1748. 
139. Kulonen, K., Boldina, I., 1993. Differentiation of two rabies strains in Estonia 
with reference to recent finish isolates. J. Wildlife Dis. 29, 209-213. 
140. Kulonen, K., Fekadu, M., Whitfield, S., Warner, C.K., 1999. An evaluation of 
immunofluorescence and PCR methods for detection of rabies in archival 
carnoy-fixed, paraffin-embedded brain tissue. J. Vet. Med. 46, 151-155. 
  
72
141. Kumar, S., Tamura, K., Nei, M., 2004. MEGA 3: Integrated software for 
Molecular Evolutionary Genetics Analysis and sequence alignment. 
Briefings in Bioinformatics. 5, 150-163. 
142. Kuzmin, I.V., Orciari, L.A., Arai, Y.T., Smith, J.S., Hanlon, C.A., Kameoka, 
Y., Rupprecht, C.E., 2003. Bat lyssaviruses (Aravan and Khujand) from 
Central Asia: phylogenetic relationships according to N, P and G gene 
sequences. Virus Res. 97, 65-79. 
143. Kuzmin, I.V., Botvinkin, A.D., McElhinney, L.M., Smith, J.S., Orciari, L.A., 
Hughes, G.J., Fooks, A.R., Rupprecht, C.E., 2004. Molecular epidemiology 
of terrestrial rabies in the former Soviet Union. J. Wildlife Dis. 40, 617-631. 
144. Kuzmin, I.V., Hughes, G.J., Botvinkin, A.D., Orciari, L.A., Rupprecht, C.E., 
2005. Phylogenetic relationships of Irkut and West Caucasian bat viruses 
within the Lyssavirus genus and suggested quantitative criteria based on 
the N gene sequence for lyssavirus genotype definition. Virus Res. 111, 28-
43. 
145. Lafon, M., Wiktor, T.J., Macfarlan, R.I., 1983. Antigenic sites on the CVS 
rabies virus glycoprotein: analysis with monoclonal antibodies. J. Gen. Virol. 
64, 843-851. 
146. Lafon, M., Ideler, J., Wunner, W.H., 1984. Investigation of the antigenic 
structure of rabies virus glycoprotein by monoclonal antibodies. Dev. Biol. 
Stand. 57, 219-25. 
147. Lambot, M., Blasco, E., Barrat, J., Cliquet, F., Brochier, B., Renders, C., 
Krafft, N., Bailly, J., Munier, M., Aubert, M.F., Pastoret P.P., 2001. Humoral 
and cell-mediated immune responses of foxes (Vulpes vulpes) after 
experimental primary and secondary oral vaccination using SAG2 and V-
RG vaccines. Vaccine. 19, 1827-1835. 
148. Larson, J.K., Wunner, W.H., Otvos, L., Ertl, H., 1991. Identification of an 
immunodominant epitope within the phosphoprotein of rabies virus that is 
recognized by both class I- and Class II-restricted T cells. J. Virol. 65, 5673-
5679. 
149. Linhart, S.B., King, R., Zamir, S., Naveh, U., Davidson, M., Perl, S., 1997. 
Oral rabies vaccination of red foxes and golden jackals in Israel: preliminary 
bait evaluation. Rev. Sci. Tech. Off. Int. Epiz. 16, 874-880. 
150. Lodmell, D.L. 1999. Rabies DNA vaccines for protection and therapeutic 
treatment. Expert. Opin. Investig. Drugs. 8, 115-122. 
151. Lodmell, D.L., Ray, N.B., Ulrich, J.T., Ewalt, L.C., 2000. DNA vaccination of 
mice against rabies virus: effects of the route of vaccination and the 
adjuvant monophosphoril lipid A (MPL®). Vaccine. 18, 1059-1066. 
152. Lodmell, D.L., Ewalt, L.C., 2001. Post-exposure DNA vaccination protects 
mice against rabies virus. Vaccine. 19, 2468-2473. 
153. Lodmell, D.L., Parnell, M.J., Bailey, J.R., Ewalt, L.C., Hanlon, C.A., 2002. 
Rabies DNA vaccination of non-human primates: post-exposure studies 
using gene gun methodology that accelerates induction of neutralizing 
antibody and enhances neutralizing antibody titers. Vaccine. 20, 2221-2228. 
154. Loza-Rubio, E., Rojas-Anaya, E., Banda-Ruíz, V.M., Nadin-Davis, S.A., 
Cortez-García, B. 2005. Detection of multiple strains of rabies virus RNA 
using primers designed to target Mexican vampire bat variants. Epidemiol. 
Infect. 133, 927-934. 
  
73
155. Loza-Rubio, E., Rojas-Anaya, E., Gomez Nieto, L., Olivera Flores, M.T.J., 
Gomez, M.A., 2007. Development of and edible rabies vaccine in maize, 
using Vnukovo strain. Towards the elimination of Rabies in Eurasia. Joint 
OIE/WHO/EU International Conference. Paris, 27-30 May. Abstract Book, 
71. 
156. Lumio, J., Hillbom, M., Roine, R., Ketonen, L., Haltia, M., Valle, M., 
Neuvonen, E., Lahdevirta, J., 1986. Human rabies of bat origin in Europe. 
Lancet. 1, 378. 
157. Lumlertdacha, B., Boongird, K., Wanghongsa, S., Wacharapluesadee, S., 
Chanhome, L., Khawplod, P., Hemachudha, T., Kuzmin, I., Rupprecht, C.E., 
2005. Survey for bat lyssaviruses, Thailand. Emerg. Infect. Dis. 11, 232-
236. 
158. Luo, T.R., Minamoto, N., Hishida, M., Yamamoto, K., Fujise, T., Hiraga, S., 
Ito, N., Sugiyama, M., Kinjo T., 1998. Antigenic and functional analyses of 
glycoprotein of rabies virus using monoclonal antibodies. Microbiol. 
Immunol. 42, 187-193. 
159. MacInnes, C.D., Smith, S.M., Tinline, R.R., Ayers, N.R., Bachmann, P., 
Ball, D.G., Calder, L.A., Crosgrey, S.J., Fielding, C., Hauschildt, P., Honig, 
J.M., Johnston, D.H., Lawson, K.F., Nunan, C.P., Pedde, M.A., Pond, B., 
Stewart, R.B., Voigt, D.R., 2001. Elimination of rabies from red foxes in 
eastern Ontario. J. Wildlife Dis. 37, 119-132. 
160. Madhusudana, S.N., Saraswati, S., 2003. Development and evaluation of a 
latex agglutination test for rabies antibodies. J. Clin. Virol. 27, 129-135. 
161. Makarov, V.V., Vorob’ev, A.A., 2004. Actual problems of rabies: natural 
niduses, methodology of investigation and control in the Central Russia. 
Veterinary Pathology. 3, 102-116. 
162. Mansfield, K.L., Racloz, V., McElhinney, L.M., Marston, D.A., Johnson, N., 
Ronsholt, L., Christensen, L.S., Neuvonen, E., Botvinkin, A.D., Rupprecht, 
C.E., Fooks, A.R., 2006. Molecular epidemiological study of Arctic rabies 
virus isolates from Greenland and comparison with isolates from throughout 
the Arctic and Baltic regions. Virus Res. 116, 1-10. 
163. Masson, E., Cliquet, F., Aubert, M., Barrat, J., Aubert, A., Artois, M., 
Schumacher, C.L., 1996. Safety study of the SAG2 rabies virus mutant in 
several non-target species with a view to its future use for the immunization 
of foxes in Europe. Vaccine. 14, 1506-1510. 
164. Masson, E., Bruyere-Masson, V., Vuillaume, P., Lemoyne, S., Aubert, M., 
1999. Rabies oral vaccination of foxes during the summer with the VRG 
vaccine bait. Vet. Res. 30, 595-605. 
165. Matouch, O., 1996. Rabies control by oral vaccination in the Czech 
Republic. WHO Conference on Oral Immunization of Foxes Against Rabies 
in Central and Eastern Europe. Slovenia, Portroz, 12-15. 
166. Matsumoto, S., 1962. Electron microscopy of nerve cells infected with street 
rabies virus. Virology. 17, 156-158. 
167. Matter, H.C., Schumacher, C.L., Kharmachi, H., Hammami, S., Tlatli, A., 
Jemli, J., Mrabet, L., Meslin, F.X., Aubert, M.F., Neuenschwander, B.E., 
Hicheri, K.E., 1998. Field evaluation of two bait delivery systems for the oral 
immunization of dogs against rabies in Tunisia. Vaccine. 16, 657-665. 
168. McColl, K.A., Tordo, N., Aguilar Setien, A., 2000. Bat Lyssavirus infections. 
Rev. Sci. Tech. Off. Int. Epiz. 19, 177-196. 
  
74
169. McElhinney, L.M., Marston, D., Johnson, N., Black, C., Matouch, O., 
Lalosevic, D., Stankov, S., Must, K., Smreczak, M., Zmudzinski, I.F., 
Botvinkin, A., Aylan, O., Vanek, E., Cliquet, F., Muller, T., Fooks, A.R., 
2006. Molecular epidemiology of rabies viruses in Europe. Dev. Biol. 125, 
17-28. 
170. McGettigan, J.P., Pomerantz, R.J., Siler, C.A., McKenna, P.M., Foley, H.D., 
Dietzschold, B., Schnell, M.J., 2003. Second-generation rabies virus-based 
vaccine vectors expressing human immunodeficiency virus type 1 gag have 
greatly reduced pathogenicity but are highly immunogenic. J. Virol. 77, 237-
44. 
171. Mebatsion, T., Frost, J.W., Krauss H., 1989. Enzyme-linked immunosorbent 
assay (ELISA) using staphylococcal protein A for the measurement of 
rabies antibody in various species. Zentralbl. Veterinarmed B. 36, 532-536. 
172. Mebatsion, T., Cox, J.H., Frost, J.W., 1992. Isolation and characterization of 
115 street rabies virus isolates from Ethiopia by using monoclonal 
antibodies: identification of 2 isolates as Mokola and Lagos bat viruses. J. 
Infect. Dis. 166, 972-977. 
173. Mebatsion, T., Cox, J.H., Conzelmann, K.K., 1993. Molecular analysis of 
rabies-related viruses from Ethiopia. Onderstepoort J. Vet. Res. 60, 289-
294. 
174. Mebatsion, T., Weiland, F., Conzelmann, K., 1999. Matrix protein of rabies 
virus is responsible for the assembly and budding of bullet-shaped particles 
and interacts with the transmembrane spike glycoprotein. J. Virol. 73, 5673-
5679. 
175. Meslin, F.X., Fishbein, D.B., Matter, H.C., 1994. Rationale and prospects for 
rabies elimination in developing countries. In: Lyssaviruses. Rupprecht, 
C.E., Dietzchold, B., Koprowski, H. (Eds.) Springer, NY, USA, pp. 1-26. 
176. Metlin, A.E., Holopainen, T., Tuura, S., Ek-Kommonen, C., Huovilainen, A., 
2006. Imported case of equine rabies in Finland: clinical course of the 
disease and the antigenic and genetic characterization of the virus. J. 
Equine Vet. Sci. 26, 584-587. 
177. Metlin, A.E., Rybakov, S.S., Gruzdev, K.N., Egorov, A.A., Chepurkin, A.V., 
2007. Liquide-phase variant of the fluorescent antibody test for rabies 
diagnosis. Veterinary. 7, 56-59. 
178. Metlin, A.E., Rybakov, S.S., Gruzdev, K.N., Mikhalishin, V.V., Huovilainen, 
A., Neuvonen, E. Scientific Finnish-Russian collaboration programme on 
rabies: the outcome of five years and future prospects. Dev. Biol. in press. 
179. Miah, A., 2005. Bat rabies – the Achilles heel of a viral killer? Lancet. 366, 
876-877. 
180. Modelska, A., Dietzschold, B., Sleysh, N., Fu, Z.F., Steplewski, K., Hooper, 
D.C., Koprowski, H., Yusibov, V., 1998. Immunization against rabies with 
plant-derived antigen. Proc. Natl. Acad. Sci. USA. 95, 2481-2485. 
181. Moore, D.A., 1999. Spatial diffusion of raccoon rabies in Pennsylvania, 
USA. Prev. Vet. Med. 40, 19-32. 
182. Moore, S.M., Ricke, T.A., Davis, R.D., Briggs, D.J., 2005. The influence of 
homologous vs. heterologous challenge virus strains on the serological test 
results of rabies virus neutralizing assays. Biologicals. 33, 269-276. 
  
75
183. Morimoto, K., Hooper, D.G., Spitsin, S., Koprowski, H., Dietzschold B., 
1999. Pathogenicity of different rabies virus variants inversely correlates 
with apoptosis and rabies virus glycoprotein expression in infected primary 
neuron cultures. J. Virol. 73, 510-518. 
184. Mutinelli, F., Tollis, M., 1996. Rabies in Italy. WHO Conference on Oral 
Immunization of Foxes Against Rabies in Central and Eastern Europe. 
Slovenia, Portroz, 47-51. 
185. Muller, T., Schuster, P., Wenzel, U., Vos, A., Selhorst, T., Neubert, A.A. 
1999. Maternal immunity and the immune response of fox cubs (Vulpes 
vulpes) to oral vaccination against rabies. Abstracts 10th Annual Rabies in 
the Americas Meeting. USA, San Diego, 83. 
186. Muller, T.F., Schuster, P., Vos, A.C., Selhorst, T., Wenzel, U.D., Neubert, 
A.M., 2001. Effect of maternal immunity on the immune response to oral 
vaccination against rabies in young foxes. Am. J. Vet. Res. 62, 1154-1158. 
187. Muller, T., Cox, J., Peter, W., Schafer, R., Johnson, N., McElhinney, L.M., 
Geue, J.L., Tjornehoj, K., Fooks, A.R., 2004. Spill-over of European bat 
lyssavirus type 1 into a stone marten (Martes foina) in Germany. J. Vet. 
Med. B. 51. 49-54. 
188. Nadin-Davis, S.A., Sampath, M.I., Casey, G.A., Tinline, R.R., Wandeler, 
A.I., 1999. Phylogeographic patterns exhibited by Ontario rabies virus 
variants. Epidemiol. Infect. 123, 325–336. 
189. Nadin-Davis, S.A., Sheen, M., Abdel-Malik, M., Elmgren, L., Armstrong, J., 
Wandeler, A.I., 2000. A panel of monoclonal antibodies targeting the rabies 
virus phosphoprotein identifies a highly variable epitope of value for 
sensitive strain discrimination. J. Clin. Microbiol. 38, 1397-1403. 
190. Nadin-Davis, S.A., Huang, W., Armstrong, J., Casey, G.A., Bahloul, C., 
Tordo, N., Wandeler, A.I., 2001. Antigenic and genetic divergence of rabies 
viruses from bat species indigenous to Canada. Virus Res. 74, 139-156. 
191. Nadin-Davis, S.A., Simani, S., Armstrong, J., Fayaz, A., Wandeler, A.I., 
2003. Molecular and antigenic characterization of rabies viruses from Iran 
identifies variants with distinct epidemiological origins. Epidemiol. Infect. 
131, 777-790. 
192. Nagaraj, T., Vasanth, J.P., Desai, A., Kamat, A., Madhusudana, S.N., Ravi, 
V., 2006. Ante mortem diagnosis of human rabies using saliva samples: 
Comparison of real time and conventional RT-PCR techniques. J. Clin. 
Virol. 36, 17–23. 
193. Negri, A., 1903. Beitrag zum Stadium der Aetiologic der Tollwut. Ztschr F. 
Hyg. u. Infectionskr. 14, 507. 
194. Nel, L.H., Sabeta, C.T., von Teichman, B., Jaftha, J.B., Rupprecht, C.E., 
Bingham, J., 2005. Mongoose rabies in southern Africa: a re-evaluation 
based on molecular epidemiology. Virus Res. 109, 165-173. 
195. Neubert, A., Shuster, P., Muller, T., Vos, A., Pommerening, E., 2001. 
Immunogenicity and efficacy of the oral rabies vaccine SAD B19 in foxes. J. 
Vet. Med. 48, 179-183. 
196. Neville, J., 2004. Rabies in the ancient world. In: King, A.A., Fooks, A.R., 
Aubert, M., Wandeler, A.I. (Eds.). Historical perspectives of Rabies in 
Europe and the Mediterranean Basin, OIE, 1-13. 
  
76
197. Niin, E., Laine, M., Partel, A., 2007. Rabies Eradication programme in 
Estonia by means of oral vaccination of wildlife: First results. Towards the 
elimination of Rabies in Eurasia. Joint OIE/WHO/EU International 
Conference. Paris, 27-30 May Abstract Book. 41. 
198. Nogueira, Y.L., 2004. Estimate of validity of a new method for the isolation 
of rabies virus. Rev. Saude Publica. 38, 1-8. 
199. Nyberg, M., Kulonen, K., Neuvonen, E., Ek-Kommonen, C., Nuogram, M., 
Westerling, B., 1992. An epidemic of sylvatic rabies in Finland – descriptive 
epidemiology and results of oral vaccination. Acta. Vet. Scand. 33, 43-57. 
200. OIE Manual of Standards for diagnostic techniques, 2004. OIE, Geneva. 
201. Okoh, A.E., 2000. Antigenic characterization of rabies virus isolates from 
vaccinated dogs in plateau state, Nigeria. Vet. Res. Commun. 24, 203-211. 
202. Olson, C.A., Werner, P.A., 1999. Oral rabies vaccine contact by raccoons 
and nontarget species in a field trial in Florida. J. Wildlife Dis. 35, 687-695. 
203. Olson, C.A., Mitchell, K.D., Werner, P.A., 2000. Bait ingestion by free-
ranging raccoons and nontarget species in an oral rabies vaccine field trial 
in Florida. J. Wildlife Dis. 36, 734-743. 
204. Osorio, J.E., Tomlinson, C.C., Frank, R.S., Haanes, E.J., Rushlow, K., 
Haynes, J.R., Stinchcomb, D.T., 1999. Immunization of dogs and cats with 
a DNA vaccine against rabies virus. Vaccine. 17, 1109-1116. 
205. Palmer, D.G., Ossent, P., Suter, M.M., Ferrari E., 1985. Demonstration of 
rabies viral antigen in paraffin tissue sections: Comparison of 
immunofluorescence technique with the unlabeled antibody enzyme 
method. Am. J. Vet. Res. 46, 283-286. 
206. Pasteur, L., 1885. Methode pour prevenir la rage morsure. CR Acad. Sci. 
101, 722-765. 
207. Pastoret, P.P., Brochier, B., 1999. Epidemiology and control of fox rabies in 
Europe. Vaccine. 17, 1750-1754. 
208. Peharpre, D., Cliquet, F., Sagne, E., Renders, C., Costy, F., Aubert, M., 
1999. Comparison of visual microscopic and computer-automated 
fluorescence detection of rabies virus neutralizing antibodies. J. Vet. Diagn. 
Invest. 11, 330-333. 
209. Perl, D.P., 1975. The pathology of rabies in the central nervous system. In: 
Baer G.M. The natural history of rabies. Academic Press. Vol. 1. pp. 235-
272. 
210. Perrin, P., Rollin, P.E., Sureau, P., 1986. A rapid rabies enzyme immuno-
diagnosis (RREID) useful and simple technique for the routine diagnosis of 
rabies. J. Biol. Stand. 14, 217-222. 
211. Perrin, P., Jacob, Y., Aguilar-Setien, A., Loza-Rubio, E., Jallet, C., 
Desmezieres, E., Aubert, M., Cliquet, F., Tordo, N., 1999. Immunization of 
dogs with a DNA vaccine induces protection against rabies virus. Vaccine. 
18, 479-486. 
212. Poisson, N., Real, E., Gaudin, Y., Vaney, M., King, S., Jacob, Y., Tordo, N., 
Blondel, D., 2001. Molecular basis for the interaction between rabies virus 
phosphoprotein P and the dynein light chain LC8: dissociation of dynein-
binding properties and transcriptional functionality of P. J. Gen. Virol. 82, 
2691–2696. 
213. Prehaud, C., Coulon, P., LaFay, F., Thiers, C., Flamand, A., 1988. Antigenic 
site II of the rabies virus glycoprotein: structure and role in viral virulence. J. 
Virol. 62, 1-7. 
  
77
214. Rabies Bulletin Europe. Information. Surveillance. Research. 1989. 
Observations on the course of a bat rabies case in the Federal Republic in 
Germany. 13, 11. 
215. Rabies bulletin Europe. Information. Surveillance. Research. 2005. Vol. 25 
– № 4. , pp. 3-4. 
216. Rabies bulletin Europe. Information. Surveillance. Research. 2006. Vol. 30 
– № 4. pp. 21-22. 
217. Raux, H., Iseni, F., Lafay, F., Blondel, D., 1997. Mapping of monoclonal 
antibody epitopes of the rabies virus P protein. J. Gen. Virol. 78, 119-124. 
218. Ray, N.B., Ewalt, L.C., Lodmell, D.L., 1995. Rabies virus replication in 
primary murine bone marrow macrophages and in human and murine 
macrophage-like cell lines: implications for viral persistence. J. Virol. 69, 
764-72. 
219. Ray, N.B., Power, C., Lynch, W.P., Ewalt, L.C., Lodmell, D.L., 1997. Rabies 
viruses infect primary cultures of murine, feline, and human microglia and 
astrocytes. Arch. Virol. 142, 1011-1019. 
220. Ray, N.B., Ewalt, L.C., Lodmell, D.L., 1997. Nanogram quantities of plasmid 
DNA encoding the rabies virus glycoprotein protect mice against lethal 
rabies virus infection. Vaccine. 15, 892-895. 
221. Real, L.A., Henderson, J.C., Biek, R., Snaman, J., Jack, T.L., Childs, J.E., 
Stahl, E., Waller, L., Tinline, R., Nadin-Davis, S., 2005. Unifying the spatial 
population dynamics and molecular evolution of epidemic rabies virus. Proc. 
Natl. Acad. Sci. USA. 102, 12107-12111. 
222. Regulation (EC) No 998/2003 of the European Parliament and of the 
council of 26 May 2003 on the animal health requirements applicable to the 
non-commercial movement of pet animals and amending Council Directive 
92/65/EEC. 
223. Reid, F.L., Hall, N.H., Smith, J.S., Baer, G.M., 1983. Increased 
immunofluorescent staining of rabies-infected, formalin-fixed brain tissue 
after pepsin and trypsin digestion. J. Clin. Microbiol. 18, 968-971. 
224. Ronsholt, L., Sorensen, K.J., Bruschke, C.J.M., Wellenberg, G.J., Oirschot, 
J.T., Whitby, J.E., Bourhy, H., 1998. Clinically silent rabies infection in (zoo) 
bats. Vet. Rec. 142, 519-520. 
225. Ronsholt, L., 2002. A new case of European bat lyssavirus (EBL) infection 
in Danish sheep. Rab. Bull. Europe 2, 15. 
226. Russell, C.A., Smith, D.L., Childs, J.E., Real, L.A., 2005, Predictive spatial 
dynamics and strategic planning for raccoon rabies emergence in Ohio. 
PLoS Biol. 3, 0382-0388. 
227. Saengseesom, W., Mitmoonpitak, C., Kasempimolporn, S., Sitprija, V., 
2007. Real-time PCR analysis of dog cerebrospinal fluid and saliva for ante-
mortem diagnosis of rabies. Southeast Asian J. Trop. Med. Public Health. 1, 
53-57. 
228. Seif, I., Coulon, P., Rollin, P.E., Flamand, A., 1985. Rabies virulence: effect 
on pathogenicity and sequence characterization of rabies virus mutations 
affecting antigenic site III of the glycoprotein. J. Virol. 53, 926-34. 
229. Selimov, M.A., Botvinkin, A.D., Tatarov, A.G., 1983. Identification of sylvatic 
and Arctic rabies strains using monoclonal antibodies. Vopr. Virusol. 2, 243-
244. 
  
78
230. Selimov, M.A., Botvinkin, A.D., Khozinskii, V.V., Gribanova, L., 1994. New 
data on the spread of P-41-positive strains of the rabies virus in arctic and 
extra-arctic regions. Zh. Mikrobiol. Epidemiol. Immunobiol. 2, 53-56. 
231. Separovic, S., 1996. The current epizootiological situation and 
immunoprophylaxis of rabies in animals in Republic of Croatia. WHO 
Conference on Oral Immunization of Foxes Against Rabies in Central and 
Eastern Europe. Slovenia, Portroz, 44-46. 
232. Servat, A., Feyssaguet, M., Blanchard, I., Morize, J.L., Schereffer, J.L., 
Boue, F., Cliquet, F., 2007. A quantitative indirect ELISA to monitor the 
effectiveness of rabies vaccination in domestic and wild carnivores. J. 
Immunol. Meth. 318, 1-10. 
233. Setien, A.A., Brochier, B., Tordo, N., De Paz, O., Desmettre, P., Peharpre, 
D., Pastoret, P.P., 1998. Experimental rabies infection and oral vaccination 
in vampire bats (Desmodus rotundus). Vaccine. 16, 1122-1126. 
234. Schluter, H., 1996. Rabies control in eastern and central Europe. Country 
report based on questionnaire. WHO Conference on Oral Immunization of 
Foxes Against Rabies in Central and Eastern Europe. Slovenia, Portroz, pp. 
61-86. 
235. Schneider, L.G., 1975. Spread of virus within central nervous system. In: 
Baer G.M. The natural history of rabies. Academic Press, Vol. 1. 199-301. 
236. Schneider, L.G., Odegaard, O.A., Mueller, J., Selimov, M., 1985. 
Application of monoclonal antibodies for epidemiological investigations and 
oral vaccination studies. Arctic viruses. In: Kuwert, E., Merieux, C., 
Koprowski, H., Bogel, K., (Eds.). Rabies in the Tropics. Springer-Verlag, 
Berlin, pp. 47-59. 
237. Shankar, V., Bowen, R.A., Davis, A.D., Rupprecht, C.E., O’Shea, T.J., 
2004. Rabies in a colony of big brown bats (Eptesicus fuscus). J. Wildlife 
Dis. 40, 403–413. 
238. Shin, T., Weinstock, D., Castro, M.D., Hamir, A.N., Wampler, T., Walter, M., 
Kim, H.Y., Acland, H., 2004. Immunohistochemical localization of 
endothelial and inducible nitric oxide synthase within neurons of cattle with 
rabies. J. Vet. Med. Sci., 66, 539-541. 
239. Sidorov, G.N., Poleschuk, E.M., Sidorova, D.G., 2004. Natural focuses of 
rabies in Russia in the XX and beginning of XXI centuries. Veterinary 
Pathology. 3, 86-101. 
240. Sihvonen, L., Kulonen, K., Sovery, T., Nieminen, M., 1993. Rabies antibody 
titres in vaccinated reindeer. Acta Vet. Scand. 34, 199-202. 
241. Sihvonen, L., Kulonen, K., Neuvonen, E., 1994. Immunization of cattle 
against rabies using inactivated cell culture vaccines. Acta Vet. Scand. 35, 
371-376. 
242. Sihvonen, L., Kulonen, K., Neuvonen, E., Pekkanen, K., 1995. Rabies 
antibodies in vaccinated dogs. Acta. Vet. Scand. 36, 87-91. 
243. Sikes, R.K., 1962. Pathogenesis of rabies in wildlife. Comparative effect of 
varying doses of rabies virus inoculated into foxes and skunks. Am. J. Vet. 
Res. 23, 1041-1051. 
244. Sinchaisri, T.A., Nagata, T., Yoshikawa, Y., Kai, C., Yamanouchi, K., 1992. 
Immunohistochemical and histopathological study of experimental rabies 
infection in mice. J. Vet. Med. Sci. 54, 409-416. 
  
79
245. Smith, A.L., Tignor, G.H., Emmons, R.W., Woodie, J.D., 1978. Isolation of 
field rabies virus strains in CER and murine neuroblastoma cell cultures. 
Intervirology. 9, 359-361. 
246. Smith, D.L., Lucey, B., Waller, L.A., Childs, J.E., Real, L.A., 2002. 
Predicting the spatial dynamics of rabies epidemics on heterogeneous 
landscapes. Proc. Natl. Acad. Sci. USA. 99, 3668-3672. 
247. Smith, J.S., Yager, P.A., Baer, G.M., 1996. A rapid fluorescent focus 
inhibition test (RFFIT) for determining rabies virus-neutralizing antibodies. 
In: Meslin, F.-X., Kaplan, M.M., Koprowski, H., (Eds.). Laboratory 
techniques in rabies, WHO, Geneva. pp. 145-155. 
248. Smith, J.S., King, A.A., 1996. Monoclonal antibodies for the identification of 
rabies and non-rabies lyssaviruses. In: Meslin, F.-X., Kaplan, M.M., 
Koprowski, H., (Eds.). Laboratory techniques in rabies, WHO, Geneva. pp. 
181-191. 
249. Smith, J.M., McDonald, R.A., 2006. Emerging viral infections in 
transplantation. Pediatr Transplant. 10, 838-843. 
250. Smith, J.S., Orciari, L.A., Yager, P.A., Seidel, H.D., Warner, C.K., 1992. 
Epidemiologic and historical relationships among 87 rabies virus isolates as 
determined by limited sequence analysis. J. Infect. Dis. 166, 296–307. 
251. Smith, J.S., Seidel, H.D., 1993. Rabies: a new look at an old disease. Prog. 
Med. Virol. 40, 82-106. 
252. Spooner, M.H., 2003. UK has first rabies death in a century. CMAJ. 168, 
331. 
253. Staden, R, Beal, K.F., Bonfield, J.K., 2000. The Staden package, 1998. 
Meth. Mol. Biol. 132, 115-130. 
254. Steck, F., Wandeler, A., Bichsel, P., Capt, S., Schneider, L., 1982. Oral 
immunization of foxes against rabies. Zbl. Vet. Med. B. 29, 372-396. 
255. Stougaard, E., Ammendrup, E., 1998. Rabies in individual countries: 
Denmark. Rab. Bull. Europe 22, 6. 
256. Svrcek, S., Sokol, J., Lovas, B., Durove, A., Suliova, J., Zavadova, J., 
Ondrejka, R., Benisek, Z., Borsukova, O., Kubinec, J., Madar, M., 1996. 
Epizootological situation and control of rabies in animals in Slovak Republic. 
WHO Conference on Oral Immunization of Foxes Against Rabies in Central 
and Eastern Europe. Slovenia, Portroz, pp. 16-32. 
257. Tepsumethanon, V., Wilde, H., Meslin, F.X., 2005. Six criteria for rabies 
diagnosis in living dogs. J. Med. Assoc. Thai. 88, 419-422. 
258. Thomas, J.B., 1975. The serum neutralization, indirect fluorescent antibody, 
and rapid fluorescent focus inhibition test. In: Baer G.M. The natural history 
of rabies. Academic Press, Vol. 1, pp. 417-433. 
259. Thulke, H.H., Tischendorf, L., Staubach, C., Selhorst, T., Jeltsch, F., Muller, 
T., Schluter, H., Wissel, C., 1999. The spatio-temporal dynamics of a post-
vaccination resurgence of rabies in foxes and emergency vaccination 
planning. Prev. Vet. Med. 47, 1-21. 
260. Thulke, H.H., Selhorst, T., Muller, T., Wyszomirski, T., Muller, U., 
Breitenmoser, U., 2004. Assessing anti-rabies baiting - what happens on 
the ground? BMC Infect. Dis. 4, 9. 
261. Tims, T., Briggs, D.J., Davis, R.D., Moore, S.M., Xiang, Z., Ertl, H.C., Fu, 
Z.F., 2000. Adult dogs receiving a rabies booster dose with a recombinant 
adenovirus expressing rabies virus glycoprotein develop high titers of 
neutralizing antibodies. Vaccine. 18, 2804-2807. 
  
80
262. Tollis, M., Buonavoglia, C., Trani, L., Vignolo, E., 1988. Sensitivity of 
different cell lines for rabies virus isolation. J. Vet. Med. B. 35, 504-508. 
263. Tordo, N., Poch, O., Ermine, A., Keith, G., Rougeon F., 1986. Walking 
along the rabies genome: is the large G-L intergenic region a remnant 
gene? Proc. Natl. Acad. Sci. USA. 83, 3914-3918. 
264. Tordo, N., Poch, O., Ermine, A., Keith, G., Rougeon, F., 1988. Completion 
of the rabies virus genome sequence determination: highly conserved 
domains among the L (polymerase) proteins of unsegmented negative-
strand RNA viruses. Virology. 165, 565-576. 
265. Tordo, N., Poch, O., 1988. Structure of rabies virus. In: Campbell, J.B., 
Charlton K.M. (Eds.). Rabies. Boston, 25-45. 
266. Tordo, N., Bourhy, H., Sacramento, D., 1995. PCR technology for 
Lyssavirus diagnosis. In: Clewley J. et al. (Eds.). The polymerase chain 
reaction (PCR) for human viral diagnosis. London, 125-145. 
267. Tordo, N., 1996. Characteristics and molecular biology of the rabies virus. 
In: Meslin, F.-X., Kaplan, M.M., Koprowski, H., (Eds.). Laboratory 
Techniques in Rabies. Geneva, pp. 28-53. 
268. Tordo, N., Sacramento, D., Bourhy, H., 1996. The polymerase chain 
reaction (PCR) technique for diagnosis, typing and epidemiological studies 
of rabies. In: Meslin, F.-X., Kaplan, M.M., Koprowski, H., (Eds.). Laboratory 
Techniques in Rabies. Geneva, pp. 157-170. 
269. Torres-Anjel, M.J., Montano-Hirose, J., Cazabon, E.P.I., Oakman, J.K., 
Wiktor, T.J., 1984. A new approach to the pathobiology of rabies virus as 
aided by immunoperoxidase staining. Am. Assn. Vet. Lab. Diagn. 27, 1-26. 
270. Tuffereau, C., Leblois, M., Benejean, J., Coulon, P., Lafay, F., Flamand, A., 
1989. Arginine or lysine in position 333 of ERA and CVS glycoprotein is 
necessary for rabies virulence in adult mice. Virology. 172, 206-212. 
271. Umoh, J.U., Blenden, D.C., 1981. Immunofluorescent staining of rabies 
virus antigen in formalin-fixed tissue after treatment with trypsin. Bull. WHO. 
59, 737-44. 
272. Umoh, J.U., Cox, J.H., Schneider, L.G., 1990. Antigenic characterization of 
street rabies virus isolates from Nigeria using monoclonal antibodies. J. Vet. 
Med. 37, 222-228. 
273. Virus Taxonomy. Classification and Nomenclature of Viruses: The eighth 
Report of the International Committee on Taxonomy of Viruses. Part II – 
The Negative Sense Single Stranded RNA Viruses. Fauquet, C.M., Mayo, 
M.A., Maniloff, J., Desselberger, U., Ball, L.A. (Eds.). Elsevier Academic 
Press, 2005. pp. 609-614. 
274. Vos, A., Neubert, A., Aylan, O., Schuster, P., Pommerening, E., Muller, T., 
Chai Chivatsi, D., 1999. An update on safety studies of SAD B19 rabies 
virus vaccine in target and non target species. Epidemiol. Infect. 123, 165-
175. 
275. Vos, A., Muller, T., Schuster, P., Shluter, H., Neubert, A., 2000. Oral 
vaccination of foxes against rabies with SAD B19 in Europe, 1983-1998: A 
review. Vet. Bull. 70, 1-6. 
276. Vos, A., Muller, T., Selhorst, T., Schuster, P., Neubert A., Schluter H., 2001. 
Optimising spring oral vaccination campaigns of foxes against rabies. 
Dtsch. tierarztl. Wschr. 108, 55-59. 
277. Vos, A., 2003. Oral vaccination against rabies and the behavioral ecology of 
the red fox (Vulpes vulpes). J. Vet. Med. B. 50, 477-483. 
  
81
278. Vos, A., Kaipf, I., Denzinger, A., Fooks, A.R., Johnson, N., Muller, T. 2007. 
European bat lyssaviruses — an ecological enigma. Acta Chiropterologica. 
9, 283–296. 
279. Wakeley, P.R., Johnson, N., McElhinney, L.M., Marston, D., Sawyer, J., 
Fooks, A.R., 2005. Development of a Real-Time, TaqMan Reverse 
Transcription-PCR Assay for Detection and Differentiation of Lyssavirus 
Genotypes 1, 5, and 6. J. Clin. Microbiol. 43, 2786–2792. 
280. Wandeler, A.I., Capt, S., Kappeler, A., Hauser, R., 1988. Oral immunization 
against rabies: concept and first field experiments. Rev. Infect. Dis. 10. 
Suppl. 4, 649-653. 
281. Wandeler, A.I., 2000. Oral immunization against rabies: afterthoughts and 
foresight. Swiss Arch. Vet. Med. 142, 455-462. 
282. Wang, Y., Xiang, Z., Pasquini, S., Ertl, H.C., 1998. Effect of passive 
immunization or maternally transferred immunity on the antibody response 
to a genetic vaccine to rabies virus. J. Virol. 72, 1790-1796. 
283. Wang, Z.W., Sarmento, L., Wang, Y., Li, X., Dhingra, V., Tseggai, T., Jiang, 
B., Fu, Z.F., 2005. Attenuated rabies virus activates, while pathogenic 
rabies virus evades, the host innate immune responses in the central 
nervous system J. Virol. 79, 12554–12565. 
284. Warrell, M.J., Looareesuwan, S., Manatsathit, S., White, N.J., Phuapradit, 
P., Vejjajiva, A., Hoke, C.H., Burke, D.S., Warrell, D.A., 1988. Rapid 
diagnosis of rabies and post-vaccinal encephalitides. Clin. Exp. Immunol. 
71, 229-234. 
285. Warrel, D.A., Warrel, M.J., 1995. Human rabies: a continuing challenge in 
the tropical world. Schweiz. Med. Wochenschr. 125, 879-885. 
286. Webster, W.A., Casey, G.A., 1996. Virus isolation in neuroblastoma cell 
culture. In: Meslin, F.-X., Kaplan, M.M., Koprowski, H., (Eds.). Laboratory 
Techniques in Rabies. Geneva, pp. 96-103. 
287. Westerling, B., 1989. A Field trial on oral immunization of raccoon dogs and 
foxes against rabies in Finland 1988-1989. Rabies Bull. Eur. 2, 9-12. 
288. Whitby, J.E., Heaton, P.R. Black, E.M. Wooldridge, M. Mcelhinney, L.M., 
Johnstone, P., 2000. First isolation of a rabies-related virus from a 
Daubenton’s bat in the United Kingdom. Vet. Rec. 147, 385–388. 
289. WHO. Report of a WHO Consultation on intradermal application of human 
rabies vaccine. WHO, Geneva, 1995. 
290. WHO recommendations on rabies post-exposure treatment and the correct 
technique of intradermal immunization against rabies. 
WHO/EMC/ZOO.96.6. 1997. 
291. WHO Expert Consultation on Rabies: first report. WHO technical report 
series 931, 2005, Geneva, Switzerland 
292. Wiktor, T.J., Koprowski, H., 1978. Monoclonal antibodies against rabies 
virus produced by somatic cells hybridization: detection of antigenic 
variants. Proc. Nat. Acad. Sci. USA. 75, 3938-3942. 
293. Wiktor, T.J., Macfarlan, R.I., Reagan, K.J., Dietzschold, B., Curtis, P.J., 
Wunner, W.H., Kieny, M.P., Lathe, R., Lecocq, J.P., Mackett, M., Moss, B., 
Koprowski H., 1984. Protection from rabies by a vaccinia virus recombinant 
containing the rabies virus glycoprotein gene. Proc. Natl. Acad. Sci. USA. 
81, 7194-7198. 
294. Winkler, W.G., Bogel, K., 1992. Control of rabies in Wildlife. Scientific Am. 
266, 56-62. 
  
82
295. Wunner, W.H., 1991. The chemical composition and molecular structure of 
rabies viruses. In: Baer, G.M., Natural history of rabies, 2nd ed. CRC Press, 
Inc., Boca Raton, Fla. pp. 31-67. 
296. Xuan, X., Tuchiya, K., Sato, I., Nishikawa, Y., Onoderaz, Y., Takashima, Y., 
Yamamoto, A., Katsumata, A., Iwata, A., Ueda, S., Mikami, T., Otsuka, H., 
1998. Biological and immunogenic properties of rabies virus glycoprotein 
expressed by canine herpesvirus vector. Vaccine. 16, 969-976. 
297. Yang, J., Hooper, D.C., Wunner, W.H., Koprowski, H., Dietzschold, B., Fu, 
Z.F., 1998. The specificity of rabies virus RNA encapsidation by 
nucleoprotein. Virology. 242, 107-117. 
298. Yi, C.E., Ba, L., Zang, L., Ho, D.D., Chen, Z., 2005. Single amino acid 
substitutions in the severe acute respiratory syndrome coronavirus spike 
glycoprotein determine viral entry and immunogenicity of a major 
neutralizing domain. J. Virol. 79, 11638-11646. 
299. Yusibov, V., Modelska, A., Steplewski, K., Agadjanyan, M., Weiner, D., 
Hooper, D.C., Koprowski, H., 1997. Antigens produced in plants by infection 
with chimeric plant viruses immunize against rabies virus and HIV-1. Proc. 
Natl. Acad. Sci. USA. 94, 5784-5788. 
300. Zalan, E., Wilson, C., Pukitis, D., 1979. A microtest for the quantitation of 
rabies virus neutralizing antibodies. J. Biol. Standart. 7, 213-220. 
301. Zimmer, K., Wiegand, D., Manz, D., Frost, J.W., Reinacher, M., Frese, K., 
1990. Evaluation of five different methods for routine diagnosis of rabies. J. 
Vet. Med. 37, 392-400. 
